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ABSTRACT 
In recent years, kindness-based meditation practices, including loving-kindness 
meditation (LKM), have gained empirical support for decreasing depression and anxiety 
symptoms. LKM is defined as the intentional transmission of unselfish kindness toward 
all beings. It is practiced by contemplating an object of meditation (e.g., self, difficult 
person) and offering goodwill by silently repeating phrases (e.g., “May you be happy”). 
Given LKM’s focus on cultivating positive emotional states, researchers have 
hypothesized that LKM may work by increasing positive affect (PA), promoting 
cognitive and behavioral flexibility, and reducing negative affect (NA).  
This study was the first to employ a multiple baseline, single-case design to 
evaluate the acceptability and clinical efficacy of a brief, individual LKM intervention for 
individuals (N = 9) with unipolar depressive disorders, social anxiety disorder, or 
generalized anxiety disorder and low PA. Participants were randomized to a 2-, 4-, or 6-
week baseline and completed weekly assessments during baseline, 7 weeks of treatment, 
and at 1-, 2- and 4-week follow-up. LKM was hypothesized to be acceptable and 
effective for reducing depression and anxiety symptoms and increasing PA. Secondary 
hypotheses were that (1) improvements in PA would precede disorder symptom 
 viii 
improvement and (2) LKM would lead to improvements in other treatment variables 
(e.g., NA, anger, mindfulness, affective regulation styles, quality of life, etc.) 
Results revealed that the study intervention had good feasibility and acceptability. 
Per visual inspection, LKM led to improvements in principal disorder symptoms for four 
participants during treatment and five participants at follow-up (three of whom showed 
clinically reliable change). Contrary to study hypotheses, only one participant 
demonstrated reliable improvements in PA during treatment. For this participant, 
increases in PA occurred simultaneously with reductions in depression. Across 
participants, LKM exerted moderate to large effects on disorder severity, depression and 
anxiety symptoms, quality of life, mindful nonreactivity, and tolerating affective style. 
Overall, individuals with principal unipolar depressive disorders showed the strongest 
response to the study intervention. In summary, this study provided preliminary evidence 
for the effectiveness of brief, individual LKM for reducing depression and anxiety in a 
transdiagnostic outpatient sample with low positive affect.  
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INTRODUCTION 
Meditation treatments are increasingly being incorporated into cognitive-
behavioral therapy (CBT) and other psychological treatments. These practices involve the 
cultivation of awareness of one’s internal processes (e.g., thoughts, emotions) through 
attention training. Mindfulness-based meditation treatments, such as mindfulness-based 
stress reduction and mindfulness-based cognitive therapy, emphasize nonjudgmental, 
present-focused awareness and have demonstrated efficacy in treating mood and anxiety 
disorders (Hofmann, Sawyer, Witt, & Oh, 2010; Kuyken et al., 2010), as well as certain 
physical problems (e.g., chronic lower back pain; Carson et al., 2005). In recent years, 
kindness-based meditation practices, including loving-kindness meditation (LKM) and 
compassion meditation (CM), have gained empirical support for decreasing depression 
and increasing mindfulness, compassion for others, and self-compassion (Kok et al., 
2013). While mindful attention provides the foundation for these practices, LKM and CM 
are distinct from mindfulness meditation in that they are emotion-oriented meditations; 
the awareness and cultivation of certain emotional states (or the intention to cultivate an 
emotional state) is emphasized rather than an explicit focus on sensory or cognitive 
experiences (Hofmann, Grossman, & Hinton, 2011). These kindness-based meditations 
are closely related to each other and often integrated together in Buddhist meditation 
practices. However, whereas CM focuses on building sympathy for and a desire to reduce 
the suffering of the self and others, LKM focuses on generating feelings of love and 
goodwill towards the self and others. 
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Loving-Kindness Meditation (LKM) 
Loving-kindness is a translation of the Pali term metta, which is defined as the 
intentional transmission of unselfish kindness toward all beings (The Dalai Lama, 2001) 
or the wish for others to experience genuine happiness and well-being. Although LKM is 
derived from Buddhist meditation practices, it can be practiced without religious 
references by gently repeating certain phrases (e.g., “May you be free from suffering”) 
with the intention of directing positive energy (metta) towards the self, others, and 
eventually all living beings. Rather than repeating each phrase mechanically or without 
intention, practitioners are instructed to mindfully attend to the phrase, it’s meaning, and 
the feelings it evokes each time they speak or think it. These phrases can be accompanied 
by practicing a mental visualization of loving-kindness as heat, light, cooling water, or 
other personally relevant representations emanating from the heart or body outwards 
towards others (as described in Hinton, Ojserkis, Jalal, Peou, & Hofmann, 2013). 
LKM is believed to increase empathy and compassion, and to shift one’s idea of 
the self as a being who exists in relation to others, rather than in isolation (The Dalai 
Lama, 2001; Salzberg, 2002). Salzberg (2002) wrote that in practicing LKM, 
“we…become deeply aware of the suffering caused by separation and of the happiness of 
knowing our connection with all beings” (p. 6). Individuals learn to view themselves as 
people who benefit from the happiness and well-being of others (The Dalai Lama, 2001). 
As meditators practice LKM, they attend to their natural emotional reactions and strive to 
meet difficult emotions (e.g., anger, guilt, envy, yearning) with loving-kindness, which is 
believed to reduce the interference of negative emotions on the practice of mindful, 
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present-focused attention (Hofmann et al., 2011). Feelings of anger and attachment (e.g., 
over-identification with others, yearning, disappointment) in particular are presented as 
barriers to generating metta, because anger is associated with the wish to cause physical 
or emotional harm and over-attachment is associated with conditional kindness and 
goodwill towards the self and others (e.g., “I’m only lovable because you’re with me,” “I 
love you because you stay with me,” “I will love you only if you treat me kindly”). Both 
of these emotional states are directly at odds with the intention and emotional experience 
of metta. Therefore, LKM is believed to be especially effective for widening our 
understanding of others’ emotions and motivations and reducing anger, hostility, and 
anxiety, especially in the context of interpersonal relationships (Hofmann et al., 2011; 
Salzberg, 2002).  
Effects of LKM on Emotion 
Experimental studies of LKM have demonstrated that even brief interventions are 
associated with increases in positive emotions towards the self and others and decreased 
negative emotionality (for a review, see Hofmann et al., 2011). For example, one study 
randomly assigned 93 healthy, novice meditators to receive a 7-minute induction of either 
LKM (wishing health, happiness, and well-being directed toward a picture of a stranger; 
n = 45) or neutral imagery (attending to and imaging physical details of a picture of a 
stranger; n = 48) (Hutcherson, Seppala, & Gross, 2008). Before and after the intervention, 
participants rated levels of positive and negative affect, as well as explicit attitudes (i.e., 
how connected, similar, and positively they felt) towards pictures of themselves, a friend, 
and three neutral strangers. Additionally, implicit evaluative attitudes were measured 
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through the use of an affective priming task (Fazio, Sanbonmatsu, Powell, & Kardes, 
1986), in which positive and negative words (e.g., loyal, cruel) followed the presentation 
of these pictures, and participants were asked to rapidly and accurately judge the word 
valence. Participants who responded slower to negative words and faster to positive 
words after the image prime, for example, were determined to have an implicit positive 
response. Results revealed that the LKM induction, and not the neutral imagery 
induction, was associated with a significant increase in positive affect, decreased negative 
affect, and increases in both explicit and implicit positive evaluations of the self and the 
target stranger. The effects sizes of these changes were small to medium. Furthermore, in 
the LKM condition, positive changes in explicit evaluations (i.e., social connectedness) 
were mediated by increases in positive affect. Interestingly, LKM’s effects on the 
positivity of the explicit evaluation of others did not generalize to the implicit level. This 
finding could be due to the very brief nature of the study’s LKM intervention, which in 
its original form is meant to be practiced repeatedly, for a substantially longer period of 
time, and directed towards a broader range of “other” targets (e.g., neutral strangers, 
beloved ones, enemies, people around the world, all living beings). 
Other studies of LKM in nonclinical samples have demonstrated significant 
improvement in psychological and physical health (for a review, see Galante, Galante, 
Bekkers, & Gallacher, 2014) in addition to increased positive emotionality (Zeng, Chiu, 
Wang, Oei, & Leung, 2015). For example, in one workplace study of employees who 
were randomized to receive a 7-week group LKM intervention or waitlist control 
(Fredrickson, Cohn, Coffey, Pek, & Finkel, 2008), those receiving LKM demonstrated 
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increased positive emotions, sense of life purpose, social support, and decreased signs of 
physical illness, including headaches, general weakness, or congestion. Furthermore, in a 
sample of 113 undergraduate students, those who completed a 6-week group LKM 
intervention demonstrated stronger reductions in somatic symptom complaints than either 
the students who completed a 6-week Positive Emotion Regulation program or those who 
were assigned to the waitlist condition (Weytens, Luminet, Verhofstadt, & Mikolajczak, 
2014). In a sample of 32 individuals with high levels of self-criticism, those randomized 
to a 7-week LKM intervention showed larger decreases in self-criticism than the waitlist 
control group (Shahar et al., 2014). In addition, LKM was uniquely associated with 
significant, large increases in self-compassion, moderate increases in positive affect, and 
small improvements in depression symptoms. A separate study of 50 Chinese 
undergraduates revealed that, compared to those receiving no intervention (n = 25), 
students who received the 30-minute group LKM intervention three times weekly over 
four weeks showed significant increases in positive affect, decreases in negative affect, 
and increased interpersonal interactions (He et al., 2015). 
Emotion and Psychological Health 
Positive affect has garnered robust evidence as an important predictor of well-
being, health, and psychosocial functioning (Dockray & Steptoe, 2010; Garland et al., 
2010; Lyubomirsky, King, & Diener, 2005). The broaden-and-build theory (Fredrickson, 
1998, 2001) posits that, due to its evolutionary purpose of rewarding approach and 
exploratory behavior, positive affect expands people’s physiological, attentional and 
cognitive resources to result in greater behavioral flexibility. Whereas negative affect 
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typically restricts cognitive and attentional resources in order to support preparation for 
threat and fight-flight-or-freeze processes (Cacioppo & Bernston, 1999), positive affect 
has been shown to increase visual attention and cognitive flexibility (Fredrickson & 
Branigan, 2005), resulting in a broadened range of behavioral responses. In other words, 
the experience of positive affect widens one’s perceptual abilities and thoughts, and leads 
to exploratory and approach-oriented behavioral responses. Furthermore, in the context of 
interpersonal functioning, positive affect has been linked to increases in trust (Dunn & 
Schweitzer, 2005), sense of closeness with others (Waugh & Fredrickson, 2006), and an 
increased ability to associate positive attributions with others (Logie & Frewen, 2015).  
Other conceptual theories and empirical research have linked broader constructs 
of temperament (specifically, negative affect / behavioral inhibition and positive affect / 
extraversion) to the etiology and course of emotional disorders (Barlow, 2000, 2002; 
Brown, 2007). For example, research has shown that neuroticism is positively correlated 
with all emotional disorders, and the strongest associations occur between neuroticism 
and depression and generalized anxiety disorder (GAD) (Brown, 2007). Furthermore, the 
DSM-5 describes irritability, which is best defined as low-intensity anger, as a common 
feature of unipolar and bipolar mood disorders (American Psychiatric Association, 2013). 
Of the anxiety disorders, GAD is the only one that specifically includes irritability in its 
diagnostic criteria (American Psychiatric Association, 2013). However, a recent 
comprehensive review of anger in emotional disorders found irritability and anger to be a 
common emotional experience across anxiety disorders (Cassiello-Robbins & Barlow, 
2016). These authors noted that in both GAD and social anxiety disorder, individuals 
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experience greater levels of anger and greater anxiety about experiencing or expressing 
anger than nonclinical participants. Moreover, compared with nonclinical samples, 
individuals with GAD have shown more anger-related functional impairment (Hawkins 
& Cougle, 2011). Low positive affect, on the other hand has been most strongly 
associated with unipolar depression, social anxiety (Brown, 2007; Naragon-Gainey, 
Rutter, & Brown, 2014), and agoraphobia (Rosellini, Lawrence, Meyer, & Brown, 2010). 
Furthermore, a recent review identified evidence of difficulties with the cognitive and 
behavioral regulation of positive emotions in all emotional disorders (Carl, Soskin, 
Kerns, & Barlow, 2013).  
Hofmann, Sawyer, Fang, and Asnaani’s (2012) emotion dysregulation model of 
mood and anxiety disorders posits that mood and anxiety disorders are most effectively 
treated by promoting adaptive emotion regulation strategies, increasing positive affect 
and decreasing negative affect, and developing helpful affective styles. People vary not 
only in the degree to which they experience positive and negative affect, but also in their 
methods of responding to emotions, or affective style (Hofmann & Kashdan, 2010). The 
tendency to appraise emotions as unacceptable or intolerable, and then suppress or 
conceal them, is related to greater physiological arousal and rumination (Gross & 
Levenson, 1997; Rusting & Nolen-Hoeksema, 1998). In contrast, the ability to flexibly 
balance negative and positive emotional experiences (i.e., adjusting style) or to appraise 
emotions as momentary, acceptable, and tolerable (i.e., tolerating style) and allow oneself 
to fully experience emotional states, is associated with lower depression and anxiety 
symptoms, and greater subjective well-being (Aldao, Sheppes, & Gross, 2015; Hayes, 
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Luoma, Bond, Masuda, & Lillis, 2006). LKM encourages meditators to identify their 
emotions, appraise them as passing, momentary experiences, and refocus attention on 
generating intentions of kindness. In this way, LKM encourages the adoption of more 
adaptive regulating styles, such as the adjusting or tolerating strategies. 
LKM not only aims to increase nonjudgmental, present-focused awareness, but 
also seeks to increase the frequency of positive emotional experiences. Based on both 
Frederickson’s (1998, 2001) broaden-and-build conceptual theory and Hofmann and 
colleagues’ (2012) emotion regulation model of mood and anxiety disorders, these 
increases in positive affect are expected to increase cognitive and behavioral flexibility. 
In turn, increased flexibility is hypothesized to lead to the development of more adaptive 
regulation strategies for negative affect (e.g., cognitive reappraisal, acceptance) and 
subsequent decreases in negative affect and improvements in emotion disorder 
symptoms. Based on this reasoning, positive affect is a promising target in the search for 
mechanisms of LKM.  
Associations between Meditation, Brain Structure, and Connectivity 
A nascent brain imaging literature suggests that meditation practice across a 
variety of traditions is associated with larger structural regions in the brain that 
correspond to sensory awareness, emotion regulation, attentional control, memory 
reconsolidation, metacognition, and the planning of behavioral responses (for a meta-
analysis, see Fox et al., 2014). Specifically, when compared to novice meditators or 
control samples, the brains of practiced meditators (across a variety of meditation styles) 
show increased grey matter volume in the insular cortex, somatosensory cortex, and the 
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functionally related anterior precuneus. These brain regions are associated with 
interoceptive awareness (e.g., breathing, heart rate; Hölzel et al., 2008; Lazar et al., 2005; 
Luders et al., 2012) and exteroceptive awareness (e.g., touch, pain, conscious 
proprioception; Kang et al., 2013; Lazar et al., 2005; Luders et al., 2012). In addition to 
increasing awareness of sensory stimuli, meditation teaches people to nonjudgmentally 
describe and explore their internal experiences. Indeed, one study found that practitioners 
of body-focused meditations (e.g., Vispassana or insight meditation) are more likely to 
report objective sensory qualities of uncomfortable stimuli, rather than affective and 
cognitive responses to these stimuli (Fox et al., 2012). Structural changes in the prefrontal 
cortex have also been found in meditation practitioners (Kang et al., 2013; Lazar et al., 
2005; Vestergaard-Poulsen et al., 2009) and are believed to be associated with increased 
metacognitive functioning (Fleming, Weil, Nagy, Dolan, & Rees, 2010) and the 
integration of cognitive processes into behavioral goals (Ramnani & Owen, 2004). These 
correlational findings are in the early stages of being explored in longitudinal designs, 
which may foster the examination of directional effects of meditation. A few prospective 
neuroimaging studies examining the effects of meditation practice (ranging from a couple 
hours to weeks of training) on neuroplasticity have demonstrated similar changes in grey 
matter volume and white matter connectivity compared to control conditions (Holzel et 
al., 2011a, 2011b; Tang et al., 2010; Tang, Lu, Fan, Yang, & Posner, 2012). Taken 
together, these findings shed light on possible neural bases that may explain how 
meditation helps individuals increase awareness of their internal experiences (e.g., 
thoughts, feelings, urges), as well as modify maladaptive interpretations of and affective 
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reactions to these experiences. Changing these unhelpful patterns of thinking and de-
escalating emotional responses are core strategies for current CBT for anxiety and mood 
disorders (Barlow, 2002).  
No studies have directly examined the differential effects of LKM versus other 
meditation practices on brain structure. However, one recent study explored the effects of 
LKM expertise on brain structure in 25 Chinese men (10 LKM experts versus 15 LKM 
novices). In addition to finding greater left temporal lobe volume in LKM experts versus 
novices (as is consistent with brain studies of experts in other meditation traditions), this 
study revealed that LKM experts had larger brain structures associated with social 
cognition, empathy, and emotion regulation (i.e., greater left temporal lobe volume, right 
angular gyrus volume, and posterior parahippocampal gyri volume) than novices (Leung 
et al., 2013). These particular associations appear to be unique to experts of emotion-
oriented LKM versus those of other meditation traditions. Of note, these findings were 
correlational in nature, therefore it is impossible to conclude whether LKM caused the 
brain to change or people who already possessed these structural characteristics were 
more likely to become LKM practitioners. Nonetheless, such findings suggest that LKM 
may be related to the experience of processes related to emotion regulation and social 
affiliation that are beneficial to the development and maintenance of social relationships, 
a core domain of functioning often impaired by mood and anxiety disorders.  
Effects of LKM on Psychological Disorders  
While there is some growing evidence that LKM reduces depression and anxiety 
symptoms and other negative emotion states in college and other nonclinical samples, 
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few researchers have studied the effects of LKM in clinical samples. Johnson and 
colleagues (2011) examined the effects of six 1-hour, weekly LKM sessions on negative 
symptoms of schizophrenia in 18 outpatients. Results revealed that the 16 intervention 
completers (88% of sample) showed significant decreases in negative symptoms of 
schizophrenia and increases in positive affect. This study was limited by its lack of a 
control group, its small sample size, and its lack of an independent outcome assessment. 
Another recent study (Kearney et al., 2013) investigated the effects of a 12-week group 
LKM intervention on 42 veterans with posttraumatic stress disorder (PTSD). Tolerability 
of the intervention was high; 37 participants completed the intervention (88%) and 34 
participants provided data at the 3-month follow-up (81%). Results revealed that LKM 
significantly reduced PTSD symptoms and depression symptoms across a 3-month 
follow-up period.  More recently, Hoffman and colleagues (2015) examined the effects of 
a 12-week, group LKM in pilot studies of two separate samples: the first was in an 
American community sample (n = 21; 10 completers) who endorsed experiencing 
depressed or low mood “for most of the day, nearly every day for a 1 year or longer”, and 
the second was in a German clinically depressed sample (n = 12; 8 completers). In the 
American sample, repeated measures t-tests revealed a significant increase in positive 
affect, decrease in negative affect, and marked decrease in depression symptoms 
following the intervention. In the German study sample, LKM exerted significant, 
negative effects on negative affect and symptoms of depression, and significant, positive 
effects on positive affect. The German sample’s intervention was substantially altered to 
include basic psychoeducation on depression, breathing exercises to decrease general 
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distress, and a meditation retreat. These studies were limited by their lack of a control 
group, high attrition rates (33-52%), and the use of listwise deletion to accommodate 
missing data, which resulted in biased estimates of treatment efficacy. However, the large 
effect size of the change in depression symptoms, negative affect, and positive affect in 
both groups indicates that LKM is a promising intervention for those who go on to 
complete the treatment. Taken together, these studies provide preliminary evidence that 
LKM generally tolerable and effective in reducing symptoms of depression, PTSD, and 
schizophrenia in clinical and community samples.  
The Current Study 
This study was the first to evaluate whether LKM is an acceptable and clinically 
effective intervention for individuals with unipolar depressive disorders, social anxiety 
disorder, or GAD who present with low positive affect. These disorders were chosen as 
treatment targets due to their demonstrated relationships with low positive affect 
(depression and social anxiety; Brown, 2007), irritability, and anger (depression, social 
anxiety, and GAD; Cassiello-Robbins & Barlow, 2016). The effects of a 7-session 
individual LKM intervention were evaluated using a multiple baseline design across 
participants, which allows for the examination of treatment-related changes within- and 
between-participants (Barlow, Nock, & Hersen, 2009). Participants were randomized to a 
2-, 4-, or 6-week baseline period (n = 3 per condition), to control for the effect of time on 
the outcome variables. Multiple baseline across participants single-case designs are an 
ideal method for assessing the initial feasibility and efficacy of a novel intervention on 
specific treatments targets because they allow for a detailed examination of sources of 
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variability, as well as functional relationships between treatment components and 
therapeutic outcomes.  
The primary study aims were: (1) to evaluate the feasibility, tolerability, and 
efficacy of a 7-session LKM intervention for reducing depression and anxiety disorder 
symptoms using a multiple baseline experimental design, and (2) to evaluate whether 
LKM incrementally improves week-to-week experiences of positive affect during the 
intervention. Exploratory secondary study aims were: (1) to evaluate whether increases in 
positive affect precede improvements in anxiety and depression disorder symptom 
improvement, and (2) to determine if LKM is associated with improvements in negative 
affect, anger, mindfulness, interference due to overall depression and anxiety disorder 
symptoms, emotion regulation strategies, and quality of life.  
Primary Hypotheses 
1. Participants will demonstrate reductions in disorder symptom severity. These gains 
will be maintained at 2- and 4-week follow-up. 
2. Based on previous trials of LKM in clinical samples (Johnson et al., 2011; Kearney et 
al., 2013), it was expected that LKM would demonstrate feasibility and acceptability, 
as assessed by recruitment and retention of participants and participant self-report of 
acceptability and satisfaction with the intervention on the Feedback Form at post-
treatment.  
3. It was expected that LKM, a practice of cultivating and directing positive emotions 
towards the self and others, would be associated with incremental increases in 
 14 
positive affect during the intervention period. These improvements were predicted to 
remain stable at 2- and 4-week follow-up. 
Secondary Hypotheses  
1. Increases in positive affect will precede improvements in disorder symptom severity. 
This pattern of symptom improvement would be consistent with both Frederickson’s 
(1998, 2001) broaden-and-build conceptual theory and Hofmann and colleagues’ 
(2012) emotion regulation model of mood and anxiety disorders. These theories 
predict that positive affect increases cognitive and behavioral flexibility, leading to 
more adaptive regulation strategies for negative affect (e.g., cognitive reappraisal, 
acceptance) and subsequent improvements in emotion disorder symptoms.  
2. Participants will demonstrate reductions in negative affect, anger, and interference 
due to disorder symptoms, as well as increases in mindfulness, adaptive affective 
styles (e.g., tolerating, adjusting), and quality of life.  
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METHOD 
Participants 
Participants were 11 adult (age ≥ 18) outpatients seeking services for anxiety and 
mood-related concerns at the Center for Anxiety and Related Disorders (CARD) at 
Boston University (BU). In addition, participants fulfilled the following inclusion criteria: 
(1) a principal DSM-5 diagnosis of a unipolar mood disorder (specifically, major 
depressive disorder, persistent depressive disorder, or otherwise specified depressive 
disorder), social anxiety disorder, or generalized anxiety disorder (GAD) and (2) 
demonstrated deficits in positive affect, which was defined as at least one standard 
deviation below the average “general” Positive Affect scale score for a large, 
undergraduate sample on the Positive and Negative Affect Schedule (29 or lower; 
Watson, Clark, & Tellegen, 1988). In addition, participants were only included in this 
study if they either: (1) met criteria for stability on a particular dose of psychotropic 
medications (e.g., six weeks for selective serotonin reuptake inhibitors) and were willing 
to maintain a stable dosage throughout the study, or (2) were not taking psychotropic 
medications. 
Participants were excluded from the study if they: (1) experienced current suicidal 
or homicidal ideation accompanied by associated intent or a specific plan, (2) had two or 
more hospitalizations in the last 5 years for severe psychopathology (psychosis, suicide 
attempts), (3) were currently receiving CBT or any psychotherapy to address anxiety, 
depression, or other related disorder (and were not willing to discontinue treatment), (4) 
were unwilling to refrain from initiating additional treatment during the course of the 
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study, (5) had other current or very recent symptoms that required immediate clinical 
attention, alternative treatment, and/or a higher level of care that cannot be provided 
through the study (e.g., florid delusions or hallucinations, rapid mood state, severe manic 
symptoms), (6) had a current or recent (within 3 months) history of alcohol or drug use 
disorder (exception would be alcohol, marijuana, caffeine, and/or nicotine use disorder 
with the severity specifier of mild), (7) demonstrated deficits in mindfulness that would 
prevent engagement in extended meditation exercises, defined as scoring at least one 
standard deviation below the average clinical score on the 39-item Five Facet 
Mindfulness Questionnaire (FFMQ-39; Baer, Smith, Hopkins, Krietemeyer, & Toney 
2006) Describe factor (19 or lower) or FFMQ-39 Nonreactivity factor (13 or lower; 
Curtiss & Klemanski, 2014), (9) had a previous course of LKM treatment (defined as 3 or 
more sessions) or practiced LKM at a rate greater than the standard definition of a novice 
(i.e., for more than one hour per month), (10) were not fluent English speakers (those 
unable to complete the CARD phone screen and a structured clinical interview in 
English), or (11) had emotional symptoms that are due to a medical/physical condition (in 
which case alternative treatment would be clinically indicated).  
This study enrolled nine study completers, given that two to three baselines per 
group in a single-case multiple baseline experimental design are recommended (Barlow 
et al., 2009). Study completers were defined as the participant attending all study visits 
and completing the primary outcome measures, the Depression Anxiety and Stress Scales 
(DASS; Lovibond & Lovibond, 1995) and the Positive and Negative Affect Schedule 
(PANAS; Watson et al., 1988), on the majority of weekly assessments within each study 
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phase (baseline, treatment, and follow-up). In addition, the three principal mental 
disorders included in this study were counterbalanced across baseline conditions to 
eliminate variability that could arise by including different disorders across the multiple 
baselines (i.e., studying the effects of LKM on depression with a 2-week baseline versus 
social anxiety disorder with a 2-week baseline).  
Recruitment. All study procedures were approved by the BU Institutional Review 
Board and took place at CARD. Active recruitment began in December 2016 and ended 
in mid-June 2017. During this time, patients who had previously completed an intake 
assessment at CARD and who were diagnosed with principal unipolar depression, GAD, 
or social anxiety were contacted if they had also expressed interest in participating in 
research treatment studies during their intake. This study was also advertised through 
flyers posted on community bulletin boards and BU listservs. Advertisements included a 
brief description of the study and the screening question, “Do you feel depressed, 
worried, or socially anxious and also have trouble feeling positive emotions?” 
Recruitment materials mentioned that participants would receive up to $90 for 
completing study procedures. 
Interested individuals completed a brief phone screen and online screening 
questionnaires to determine their potential eligibility for the study. Of the 43 individuals 
who completed an initial phone screen, fifteen (35%) completed all phone screen 
procedures (including online questionnaires assessing mindfulness qualities and positive 
affect) and were offered an in-person visit to sign informed consent and complete a 
diagnostic assessment. The remaining individuals were either found ineligible (n = 19; 
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44%), not interested (n = 6; 14%), or were lost to follow-up before completing the phone 
screen (n = 3; 7%). Reasons for ineligibility included low scores on requisite subscales of 
the FFMQ-39 (n = 12), no deficits in positive affect (n = 4), or a presenting concern other 
than depression, worry, or social anxiety (n = 3).  
Informed consent was obtained in-person prior to beginning study procedures. 
Participants referred through CARD did not require an additional diagnostic assessment 
if they had completed an intake evaluation within three weeks of the screening visit. 
Thirteen individuals presented for an in-person screening visit and two were found 
ineligible (one due to low mindfulness scores and one due to a moderate alcohol use 
disorder). The remaining eleven participants were randomized to a baseline condition (2-, 
4-, or 6-weeks). One of the randomized participants completed four weeks of baseline 
assessments, but then did not present for the first study treatment session and was lost to 
follow-up. Another participant completed a 6-week baseline and three sessions of the 
study intervention, then discontinued treatment due to reported anxiety about the 
homework assignments and a preference to seek supportive talk therapy instead.  
Patient demographics and diagnoses. Characteristics of study participants who were 
randomized to baseline conditions (including 9 study completers and 2 non-completers) 
are presented in Table 1. The average age for study completers (n = 9) was 25.3 years 
(SD = 4.53, range = 21 to 34). Non-completers (Participants 9 and 13) did not 
significantly differ from completers in age, t(9) = 2.15, p = .06. The majority of study 
completers identified their both their sex and gender as female (n  = 5), whereas 4 
completers identified both their sex and gender as male. Six completers identified their 
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race as Caucasian, 3 identified as Asian, 1 identified as African-American, and 1 as 
Other. Of the 9 completers, 2 participants identified their ethnicity as Hispanic or Latino. 
Most participants reported their marital status as single (88.9%), and one was engaged. 
Two-thirds of study completers held part-time jobs or were students, and one-third of 
completers worked full-time. Completers and non-completers did not appear to differ 
significantly these demographic variables.  
Mental disorders were assessed by doctoral students or doctoral-level clinical 
psychologists using the Anxiety and Related Disorders Interview Schedule for DSM-5 
(ADIS-5; Brown & Barlow, 2014), a reliable and valid semi-structured clinical interview 
that assesses DSM-5 anxiety, mood, and related disorders (e.g., obsessive-compulsive, 
trauma or stressor-related, alcohol and substance use; for further details, see Measures 
below). Clinicians assign all principal and additional diagnoses a clinical severity rating 
(CSR) that represents the level of distress or impairment associated with the specific 
disorder scale. CSRs of 4 (definitely disturbing/disabling) or higher indicate the presence 
of a clinically significant mental health disorder. The average number of mental disorder 
diagnoses at baseline was 2.55 (SD = 1.33) for study completers. For completers, the 
severity of the principal disorder diagnosis was rated at a mean CSR of 5.33 (SD = .87), 
indicating a moderate level of distress and functional impairment. Principal disorder 
diagnoses included GAD (n = 3), social anxiety disorder (n = 3), major depressive 
disorder (n = 2), and other specified depressive disorder (n = 1). The most common 
additional diagnosis was GAD (n = 4). Other additional disorder diagnoses among 
  
Table 1. Demographic Information and Characteristics of Participants Randomized to Baseline Conditions (N = 11) 
Note. F = female; M = male; C = Caucasian; A = Asian; AA = African-American; NH = non-Hispanic/Latino; H = Hispanic/Latino; S = 
Single; E = Engaged; PT = part-time; FT = full-time; SOC = social anxiety disorder; CSR = clinical severity rating; MDD = major 
Participant Age Sex Race Ethnicity Marital 
Status 
Employment 
Status 
Principal 
Diagnosis - 
CSR 
Additional 
Diagnoses - 
CSR 
Psychiatric 
Medications 
Referral 
Source 
1 28 F C NH S PT / Student SOC – 6 PTSD – 5  
GAD – 4  
PDD – 4  
 
Propranolol 
PRN 
CARD 
2 30 M C H S FT  MDD – 6 GAD – 5 
SOC – 5 
BDD – 4 
 
N CARD 
4 22 F A NH S PT / Student GAD – 6 OSDD – 4 
 
N CARD 
5 21 M C NH S Student OSDD – 4 -  
 
N CARD 
7 34 F C NH E FT SOC – 6 GAD – 6 
BDD – 4 
 
N CARD 
8 26 M C H S Student GAD – 5        - 
 
Wellbutrin 
150mg 
CARD 
9 50 M C NH S FT PDD – 6 SOC – 6 
SPEC – 4 
 
N Online 
10 23 F A NH S PT / Student SOC – 5 GAD – 4 N Flyer 
11 21 M A NH S Student MDD – 6  SOC – 6 
OSAD – 6 
BED – 4 
 
N CARD 
12 23 F AA NH S FT GAD – 4       - 
 
N CARD 
13 25 F C NH S FT GAD – 5  MDD – 4  N CARD 
  
depressive disorder; GAD = generalized anxiety disorder; OSDD = other specified depressive disorder; PDD = persistent depressive 
disorder; PTSD = posttraumatic stress disorder; BDD = body dysmorphic disorder; SPEC = specific phobia; OSAD = other specified 
anxiety disorder; BED = binge eating disorder; CARD = Center for Anxiety and Related Disorders 
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completers included a unipolar mood disorder (n = 2), social anxiety disorder (n = 2), 
body dysmorphic disorder (n = 2), PTSD (n = 1), binge eating disorder (n = 1), and other 
specified anxiety disorder (n = 1). Two completers were taking psychoactive medications 
at stable doses before and during the study. 
Measures 
Primary Outcome Measures 
 Anxiety and Related Disorders Interview Schedule for DSM-5 (ADIS-5; Brown & 
Barlow, 2014). The ADIS-5 is a semi-structured interview designed to establish current 
DSM-5 diagnoses of anxiety, mood, obsessive-compulsive, trauma, and related disorders 
(e.g., somatic symptom, alcohol and substance use), and to screen for other disorders 
(e.g., psychotic disorders). Clinicians assign each disorder a clinical severity rating (CSR) 
ranging from 0 (Absent/none) to 8 (Very severely disturbing or disabling) indicate the 
degree of interference and distress associated with disorder symptoms. CSRs of 4 
(definitely disturbing/disabling) or above indicate the presence of a clinical diagnosis. 
Although the ADIS-5 was just recently published along with DSM-5, the ADIS-IV-L, a 
previous version based on DSM-IV, has been shown to have good or excellent diagnostic 
reliability for most anxiety and mood disorders (κs = .67-.86; Brown, Di Nardo, Lehman, 
& Campbell, 2001).  
Depression Anxiety Stress Scales (DASS; Lovibond & Lovibond, 1995). The 
DASS is a 21-item self-report scale that assesses levels of depression (DASS-D), general 
anxiety (DASS-A), and general tension/negative affect symptoms (DASS-S) over the 
past week. Sample items include: “I felt down-hearted and blue” (DASS-D), “I felt 
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scared without any good reason” (DASS-A), and “I found it hard to wind down” (DASS-
S). Participants are asked to rate items using a 4-point Likert-type scale ranging from 0 
(did not apply to me at all) to 3 (applied to me very much, or most of the time). 
Exploratory and confirmatory factor analyses in a variety of samples have supported this 
three-factor structure (e.g., (Brown, Chorpita, Korotitsch, & Barlow, 1997; Lovibond & 
Lovibond, 1995). 
Positive and Negative Affect Schedule (PANAS; Watson et al., 1988). The 
PANAS is a commonly used, 20-item self-report scale that assesses positive and negative 
affect (PA and NA, respectively). Each item is an affective adjective (e.g., cheerful, sad, 
timid), and participants are asked to rate, using a Likert-type scale from 1 (very slightly 
or not at all) to 5 (very much), the extent to which they have “felt this way” in a specified 
time period (for this study, “the past week”). The PA and NA scales have demonstrated 
good reliability and convergent and discriminant validity (Watson et al., 1988).  
Brief Depression, Anxiety, and Positive Emotion Likert Scales. Participants 
provided daily ratings of their experience of anxiety, depression, and positive emotions 
using a 5-point Likert scale, ranging from 1 (not at all anxious or depressed) to 5 
(extremely anxious or depressed). In addition, participants provided Likert-scale ratings 
for how often they have experienced positive emotions today, from 1 (very slightly or not 
at all) to 5 (very much). The anchors for the positive affect item were based on PANAS 
anchors. These items were adapted from Visual Analog Scales (VAS), which are single-
item instruments commonly used to reliably assess dimensional levels of subjective 
psychological experiences (e.g., depression, anxiety, pain, distress etc.; Cella & Perry, 
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1986; Wewers & Lowe, 1990). A recent large epidemiological study of anxiety 
assessment found that the VAS and the 5-point Likert scales detailed above function as 
equivalent measures of anxiety that strongly correlate with the State-Trait Anxiety 
Inventory (Davey, Barratt, Butow, & Deeks, 2007).  
 Client Satisfaction Questionnaire (CSQ-8; Larsen, Attkisson, Hargreaves, & 
Nguyen, 1979). The CSQ-8 is an 8-item, unidimensional self-report questionnaire that 
measures patients’ satisfaction with treatment. Items are rated on a 4-point Likert type 
scale that ranges from 1 (No / Poor / Dissatisfied) to 4 (Yes / Excellent / Very Satisfied), 
with anchors varying to fit each treatment question.  
Participant Feedback Form. This is a self-report form intended to measure 
participants’ experiences with the intervention (see Appendix A). Participants will 
provide qualitative feedback regarding what they found most and least helpful about the 
study intervention, as well as what modifications they would suggest to the intervention. 
Secondary Outcome Measures  
Dispositional Positive Emotion Scales (DPES; Shiota, Keltner, & John, 2006). 
The DPES is a 38-item self-report measure comprised of seven subscales measuring 
distinct positive emotional traits: joy, contentment, pride, love, compassion, amusement, 
and awe.  Each subscale consists of 5-6 items that assess trait characteristically associated 
with each emotion. Sample items from the Contentment scale include: “My life is very 
fulfilling” and “I am generally a contented person.” Subscales have demonstrated 
acceptable reliability and convergent and discriminant validity (Shiota et al., 2006).    
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State Trait Anger Expression Inventory 2 (STAXI-2; Spielberger, 1999). The 
STAIX-2 is a widely used, 44-item self-report measure that assesses trait anger, state 
anger, and styles of anger expression. This study administered the 15-item State Anger 
Scale (SAS) at all weekly assessments to measure participant’s weekly experience of the 
emotion of anger and angry urges. The 10-item Trait Anger Scale (TAS) was 
administered pre- and post-treatment to measure changes in angry temperament (the 
disposition to feel angry without provocation) and angry reaction (the frequency that 
individuals feel angry while in situations that involve negative evaluations or frustration). 
The remaining subscales (anger expression subscales) were not administered to reduce 
patient burden.   
Five Facet Mindfulness Questionnaire (FFMQ-39; Baer et al., 2006). The 
FFMQ-39 is a 39-item self-report measure of trait mindfulness in daily life. Confirmatory 
factor analyses of the FFMQ-39 conducted in a non-meditating sample prior to 
mindfulness-based interventions revealed one higher-order mindfulness factor that split 
into four factors representing facets of mindfulness (Gu et al., 2016). These four factors 
include: Describing (e.g. “I’m good at finding words to describe my feelings”), Acting 
with Awareness (e.g., “I find myself doing things without paying attention”), Nonjudging 
of Inner Experience (e.g., “I disapprove of myself when I have illogical ideas”), and 
Nonreactivity to Inner Experience (e.g., “When I have distressing thoughts or images, I 
do not let myself be carried away by them”). Items are rated on a Likert-type scale 
ranging from 1 (never or very rarely true) to 5 (very often or always true). In meditating 
samples and in non-meditating samples that complete mindfulness-based interventions, a 
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five-factor hierarchical solution that includes an observing facet (e.g., “I notice the smells 
and aromas of things), best fit the data. However, one psychometric study of the FFMQ-
39 in a clinical sample with mood or anxiety disorders found that the Observing factor 
was positively associated with anxious arousal and unrelated to the Nonjudging and 
Acting with Awareness factors (Curtiss & Klemanski, 2014). A 15-item version of the 
FFMQ (FFMQ-15) was developed to reduce patient burden and is suggested for use in 
studies with repeated measures. Both versions have demonstrated at least adequate to 
good internal consistency, sensitivity to change pre- to post-treatment, and good 
convergent validity (Baer et al., 2006; Baer, Carmody, & Hunsinger, 2008; Gu et al., 
2016). In this study, the FFMQ-39 was administered to assess initial eligibility. At all 
other weekly assessments, the FFMQ-15 was used to reduce patient burden. To derive 
initial baseline mindfulness scores, FFMQ-15 scores were calculated from participants’ 
responses to the FFMQ-39. 
Subjective Symptoms Scales (SSS; Hafner & Marks, 1976). The SSS is a 5-item 
self-report measure of interference across various domains of functioning (e.g., social 
activities, family relationships, work activities, etc.) due to mental disorder symptoms 
over the past week. Items are rated using Likert-type scale ranging from 0 (not at all) to 8 
(severe). These scales have demonstrated good internal consistency in clinical samples 
(e.g., Brown, Antony, & Barlow, 1995). 
Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form (Q-LES-
Q-SF; Endicott, Nee, Harrison, & Blumenthal, 1993). The Q-LES-Q-SF is a 14-item self-
report questionnaire that assesses the following quality of life dimensions over the past 
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week: physical health, mood, work, household activities, social relationships, family 
relationships, leisure activities, daily functioning, sexual drive and interest, economic 
status, living situation, physical stability, vision, and overall sense of well-being. Items 
are rated on a Likert-type scale, ranging from 1 (very poor) to 5 (very good).  The Q-
LES-Q-SF has demonstrated excellent internal consistency and good construct validity 
(Ritsner, Kurs, Kostizky, Ponizovsky, & Modai, 2002; Stevanovic, 2011). 
Affective Style Questionnaire (ASQ; Hofmann & Kashdan, 2010). The ASQ is a 
20-item questionnaire that measures individual differences in emotion regulation 
strategies using three subscales: Concealing (i.e., a tendency to conceal or suppress the 
expression of affect), Adjusting (i.e., a tendency to flexibly manage or balance emotional 
experiences), and Tolerating (i.e., a tendency to tolerate or accept emotional experiences). 
These subscales have demonstrated good internal consistency and convergent and 
discriminant validity (Hofmann & Kashdan, 2010).  
Credibility / Expectancy Questionnaire (CEQ; Devilly & Borkovec, 2000). This 6-
item questionnaire measures treatment credibility (how logical and believable the 
treatment is) and expectancy (how much treatment is expected to improve symptoms).  
Items are rated using a 9-point Likert-type scale ranging from 1 (not at all) to 9 (very). 
The three credibility items of the CEQ ask participants to rate how logical the treatment 
seems, how successful they think it will be in reducing their symptoms, and how 
confidence they would be in recommending the therapy to a friend who experiences 
similar problems. The three expectancy items ask participants to rate how much they 
think symptom improvement will occur, how much they feel therapy will help reduce 
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symptoms, and how much they feel that symptoms improvement will occur. The two 
factors have demonstrated good internal consistency and test-retest reliability. 
Study Intervention  
The practice of LKM entails holding the object of meditation in mind (e.g., a 
beloved one, a difficult person, the self, etc.) while sustaining intentions of goodwill, 
remaining aware of internal reactions that arise, and responding to these reactions with 
kindness. Positive intentions and emotions are gently evoked by repeating phrases of 
unselfish goodwill (e.g., “May you be happy”) while focusing one’s thoughts on a 
specific object of meditation (e.g., a benefactor). With practice, the intention of metta is 
often accompanied by pleasant emotions, such as happiness, love, joy, contentment, and 
serenity, and aversive reactions are soothed with kindness.   
Session-by-session description of study intervention. A basic overview of this 
intervention is provided below; please refer to Table 2 for a brief outline of session 
content and Appendix B for a more detailed protocol outline. This protocol was adapted 
with permission from Kearney and colleagues’ (2013) 12-session group LKM 
intervention for veterans with PTSD. Session structure, introduction of LKM objects, and 
supplemental learning materials (e.g., educational handouts, reflection exercises, poems 
related to LKM concepts) followed this protocol as closely as possible and were 
enhanced with teachings adapted from Salzberg’s (2002) book.  
Given that mindfulness functions as an essential attentional foundation for 
emotion-focused LKM exercises, Session 1 consisted of an introduction to mindfulness 
meditation (with psychoeducation about the skill and practice exercises). Next, an  
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Table 2. Summary of Protocol Session Content 
Session Number Session Content 
1 
 
1. Introduction to treatment procedures 
2. Provide rationale for meditation treatment and discuss 
treatment expectations 
3. Introduction to mindfulness / discuss qualities of mindfulness 
4. Complete 2 mindfulness exercises 
a. Raisin Exercise (e.g., mindfully eating a raisin) 
b. Body Scan Exercise (e.g., mindfully attending to 
sensations in the body) 
5. Assign homework 
6. Discussion of closing poem 
 
2 
 
1. Opening mindfulness of breath meditation 
2. Homework review 
3. Introduction to lovingkindness meditation (LKM) with 
definition of metta. Provide an explanation to participants 
about the rational of this mediation and the process  
4. LKM with focus on a benefactor 
5. Assign homework 
6. Discussion of closing poem & mindfulness of breath 
meditation 
 
3 
 
1. Opening mindfulness of breath meditation 
2. Homework review 
3. Discussion of the hindrances to lovingkindness (desire, 
attachment, aversion, anger), and countering those hindrances 
in LKM practice 
4. Introduction of LKM with focus on beloved one practice 
5. LKM with focus on a beloved one 
6. Assign homework 
7. Discussion of closing poem & mindfulness of breath 
meditation 
 
4 
 
1. Opening mindfulness of breath meditation 
2. Homework review 
3. Introduction of / preparation for LKM with focus on self. 
4. LKM with focus on the self 
5. Assign homework 
6. Discussion of closing poem & mindfulness of breath 
meditation 
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Note. LKM = loving-kindness meditation. Protocol content was adapted from Kearney 
and colleagues’ (2013) 12-session group LKM intervention. Session length was 75 ± 15 
minutes. 
 
 
 
 
 
5 
 
 
 
 
 
 
1. Opening mindfulness of breath meditation 
2. Homework review 
3. Introduction of LKM with focus on neutral person. 
4. LKM with focus on neutral person. 
5. Assign homework 
6. Discussion of closing poem & mindfulness of breath 
meditation 
 
6 
 
1. Opening mindfulness of breath meditation 
2. Homework review 
3. Introduction of / preparation for LKM with focus on difficult 
person(s). 
4. LKM with focus on difficult person(s). 
5. Assign homework 
6. Discussion of closing poem & mindfulness of breath 
meditation 
 
7 
 
1. Opening mindfulness of breath meditation 
2. Homework review 
3. Introduction of LKM with focus on groups of people and all 
living beings. 
4. LKM with focus on groups of people, then expanding to all 
living beings. 
5. Discussion of experience in treatment (progress in treatment, 
overcoming obstacles, impact of meditation on daily 
experiences) and reactions to ending treatment 
6. Discuss plan for continued LKM practice 
7. Final poem and closing meditation 
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introduction to and rational for LKM were introduced (Session 2). Traditionally, LKM 
sessions progress from cultivating and directing loving-kindness feelings initially 
towards the self, then a benefactor, a neutral person, a difficult person (i.e., someone who 
has inflicted emotional pain), to different groups of people (e.g., people of different 
racial/ethnic groups, gender identity, nation of origin, etc.), and then to all living beings. 
Given the difficulties that those with higher levels of emotional disturbance (i.e., 
depression symptoms) have reported with directing LK towards the self (see Hofmann et 
al., 2015), sessions of LKM began by targeting a benefactor, or person who has helped or 
guided the participant in some way and consequently evokes positive emotions in the 
participant. Session exercises then progressed by extending the length of the meditation 
while periodically switching the object of meditation, such that the metta that participants 
have generated towards a beloved one is produced, examined, and then transferred to 
increasingly difficult meditation targets. For example, within one session, participants 
could be instructed to intentionally direct metta towards a beloved person, then towards a 
neutral person who evokes neither negative nor positive reactions, then towards a person 
who has caused emotional pain, etc. LKM exercises were practiced during each session 
and objects of meditation were layered across session practices by hypothesized increases 
in difficulty: LK towards the benefactor (Session 2), LK towards a beloved one (Session 
3), LK towards the self (Session 4), LK towards a neutral person (Session 5), LK towards 
a difficult person (Session 6), and LK towards groups of people and all beings (Session 
7). At each session, reactions to the meditation exercises were processed and practice 
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exercises were assigned for completion between sessions. Practice exercises included 
both formal LKM practice using recordings provided to participants, as well as 
assignments to monitor emotional reactions and apply LKM informally during everyday 
activities.  
Procedure 
As previously mentioned, participants were recruited from adults seeking services 
for anxiety and mood-related at CARD, through flyers, and also online BU listservs. For 
participants who previously completed an intake assessment at CARD, the following 
procedure was followed. At the intake assessment, a clinical psychologist or advanced 
doctoral student who has undergone strict certification training for ADIS-5 administration 
conducted an ADIS-5 interview with each participant. Following the intake assessment, 
consensus principal and additional diagnoses were assigned at the CARD clinical staffing 
meeting (chaired by Timothy A. Brown, Psy.D.). Participants with eligible mental 
disorder diagnoses were contacted by the first author within three weeks of the staffing 
meeting. The first author provided information about study procedures, conducted a brief 
phone screen, and administered online screening measures (FFMQ-39; PANAS). Eligible 
participants were invited to attend an in-person screening visit. At that time, participants 
provided informed consent and study eligibility was confirmed by inclusion and 
exclusion criteria.  
For participants who did not complete prior intake assessments at CARD, a phone 
screen was completed first, and potentially eligible participants were invited to CARD for 
a screening visit. At this visit, informed consent was obtained, the FFMQ-39 and PANAS 
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questionnaires were administered if not previously completed, and the first author (who is 
ADIS-5 certified) conducted a diagnostic intake assessment. Eligible participants were 
randomized to one of three baseline conditions (2-, 4-, or 6-week baseline), and then 
completed the initial baseline self-report questionnaires.  
During the baseline and intervention phases, primary outcome variables (DASS 
and PANAS) and secondary outcome variables (FFMQ-15, STAIX-2 SAS, SSS, and Q-
LES-Q-SF) were assessed weekly and one-item measures of depression, anxiety, and 
positive affect were assessed daily to permit the analysis of functional relationships 
between specific treatment components, individual factors, and therapeutic outcomes. In 
addition, secondary outcome variables assessing trait constructs (DPES and STAIX-2 
TAS) and affective styles (ASQ) were measured pre- and post-intervention (before 
Session 1 and one week after Session 7, respectively). All self-report questionnaires were 
administered on the online survey software Qualtrics, either administered on a computer 
at CARD (for those assessments coinciding with treatment sessions) or delivered via 
email. The post-treatment assessment also included self-report measures of satisfaction 
with treatment, feedback on the study intervention, and a clinician-rated diagnostic 
interview (ADIS-5) conducted in-person or over the phone by a trained independent 
evaluator to assess anxiety and depression disorder symptoms and clinical severity. 
Finally, follow-up assessment at 2- and 4-weeks post-treatment consisted of self-report 
questionnaires measuring primary and secondary outcomes. Participants received modest 
compensation for completing the following study milestones: (1) all baseline 
questionnaires ($20), (2) mid-treatment questionnaires ($20), (3) post-treatment 
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assessment ($30), and (4) 2-week and 4-week follow-up questionnaires ($20), for a total 
of $90 for completion of all study assessments. 
In order to ensure stability of principal diagnosis disorder symptoms before 
introducing the study intervention, trend lines for DASS-D and DASS-S baseline data 
were visually inspected at the last baseline visit. If DASS-D or DASS-S symptoms 
corresponding to the principal diagnosis (DASS-D for participants with principal 
depression disorders and DASS-S for participants with principal anxiety disorders) did 
not appear stable, participants were asked to complete 1-3 additional baseline weeks to 
allow for symptom stability. In the current study, 2 participants required extended 
baselines.  
To ensure fidelity of the interventions, all sessions were audio-recorded, and 
Sharon Eldar, Ph.D. (SE), reviewed one randomly selected recording from each 
participant (10 recordings total, or 15% of total recordings). Adherence to session-
specific protocol content, session length, and non-delivery of proscribed interventions 
(e.g., formal cognitive restructuring, behavioral activation) were rated using a checklist of 
predetermined content for each session (see Appendix C). Adherence ratings ranged from 
92-100% (mean = 98.4%, mode = 100%). SE provided direct supervision of the study 
intervention during weekly meetings, and Timothy A. Brown, Psy.D., provided risk 
management and coverage as necessary.  
Prior to study enrollment, both SE and the first author attended a full-day metta 
practice retreat at the Cambridge Insight Meditation Center, completed audio training in 
LKM by Sharon Salzberg entitled, “Lovingkindness Meditation: Learning to Love 
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through Insight Meditation,” and read Salzberg’s (2002) book, Loving-Kindness: The 
Revolutionary Art of Happiness. In addition, the first author attended a 5-day metta 
retreat at the Insight Meditation Society in Barre, MA, and sustained a personal LKM 
practice for the duration of the study. 
Data Analytic Strategy 
 Data were analyzed using visual inspection techniques, in accordance with 
established guidelines for evaluating data from single-case experimental designs (SCED; 
Barlow et al., 2009; Kazdin, 2011). Prior to conducting visual inspection, the principal 
investigator completed an online training course and established reliability in visual 
analyses compared with expert raters (http://singlecase.org; Homer & Hoselton, 2012).  
To conduct between- and within-participants inspection of data from weekly outcome 
variables, data were plotted graphically, with lines connecting data points within each 
study phase (baseline, treatment, and follow-up). Horizontal, dotted lines depicting 
average scores for each phase were drawn in order to visually examine the level of 
outcome scores within phases and infer the magnitude of changes across phases. Slopes 
for each study phase, which represent the rate of symptom change, were approximated by 
visually estimating within-phase trend lines. The overall pattern of change was also 
evaluated by examining whether data appear to overlap across phases. For example, if 
scores during the treatment phase overlapped with the range of scores observed during 
the baseline phase, it can be inferred that significant change did not occur between the 
baseline and treatment phases. 
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A multiple baseline approach across individuals allows for an examination of 
between-series comparisons. If changes in the primary outcome variables occur when, 
and only when, the intervention is applied across participants in various baseline 
conditions, they can be inferred to be a result of the intervention and not simply time 
itself (Rizvi & Nock, 2008). Similarly, the change from baseline to intervention phase 
allows for within-series comparisons to examine changes in outcome variables when 
treatment is present to when it is absent within individuals.  
Visual inspection is considered a conservative approach to data analysis in SCED, 
since detection of change relies on large and consistent treatment effects (Kazdin, 2011). 
However, statistical analyses of weekly data are increasingly common (Manolov, 
Solanas, Sierra, & Evans, 2011). Therefore, multiple quantitative analyses were 
conducted to supplement visual inspection. First, reliable change index (RCI) scores were 
calculated to evaluate the clinical significance of change observed in outcome measures 
using methods outlined by Jacobson and Truax (1991). This statistic assesses whether an 
individual’s change score exceeds the range of score variability that can be accounted for 
by measurement error alone rather than clinical change. RCI is calculated by dividing the 
change in a participant’s pre- and post-intervention scores (or pre/post scores from two 
other selected time points) by the standard error of the difference (Sdiff). Sdiff requires 
knowledge of standard deviations and reliability coefficients from previously published 
psychometric analyses of or large clinical samples using each measure. It is calculated 
with the following formula:  
Sdiff  = sqrt[2(SE)2], where SE = SD sqrt(1 – rxx) 
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Here, SE is the standard error of measurement, SD is the standard deviation of the 
measure taken from the published reference sample, and rxx refers to the internal 
reliability coefficient taken from the published reference sample (Jacobson & Truax, 
1991). Standard deviations and internal consistency coefficients from the following 
psychometrics and clinical studies were used: Brown, Antony, & Barlow, 1995; Gu et al., 
2016; Harmon-Jones, 2010; Watson et al., 1988. The Sdiff for each outcome variable were 
as follows: DASS-D (Depression condition) Sdiff = 5.02; DASS-S (GAD condition) = 
4.85; DASS-S (Social Anxiety condition) Sdiff = 5.12; PANAS PA Sdiff = 5.44; PANAS 
NA Sdiff = 5.97, FFMQ-15 Describing Sdiff = 3.29; FFMQ-15 Acting with Awareness Sdiff 
= 2.55; FFMQ-15 Nonjudging of Inner Experiences Sdiff = 2.62; FFMQ-15 Nonreactivity 
to Inner Experiences Sdiff = 2.62; STAXI SAS Sdiff  = 3.34; Q-LES-Q-SF Sdiff = 5.87, SSS 
Sdiff  = 1.65. 
Absolute values of the RCI that are greater than 1.96 indicate statistically significant, 
or clinically reliable, change. In this study, RCI scores were used as follows: (1) to 
evaluate baseline stability by using the first baseline score as pre and the last baseline 
point as post, (2) to determine response to treatment by using the average of scores in the 
baseline phase as pre and the average of scores in the treatment phase as post, and (3) to 
assess the continuation or improvement of treatment effects during the follow-up phase 
by the average of baseline scores as pre and the average of follow-up scores as post.  
Second, percentage of nonoverlapping data (PND) was calculated in order aid in 
visual analysis and provide a less conservative statistical measure of change than the RCI. 
PND evaluates the effectiveness of treatment on outcome variables by calculating the 
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percentage of data from one phase (e.g., treatment) that does not numerically overlap 
with the range of data observed in the comparison phase (e.g., baseline; Tarlow & 
Penland, 2016a). PND is calculated by taking into account how scores on a particular 
measure are related to the outcome of interest (i.e., higher scores indicate clinical 
improvement) and the pattern of scores observed within a study phase (i.e., most data 
points indicating clinical deterioration rather than improvement). Therefore, when 
improvement is observed in an outcome, PND is generally calculated by examining the 
number of data points in one phase that lie above the highest value of the comparison 
phase. In contrast, when clinical deterioration is observed, PND is generally calculated by 
identifying the number of data points in one phase that fall below the lowest value in the 
comparison phase. PND was calculated in this study using an online tool specifically 
developed for SCED data that determines PND values and performs a significance test 
(Tarlow & Penland, 2016a; 2016b). PND is typically considered significant when it 
reaches 70% or higher (Scruggs & Mastropieri, 1998). To determine change produced by 
the study intervention, data points in the treatment phase were compared to the range of 
scores in the baseline phase. To determine whether any changes remained stable during 
follow-up, data points during the follow-up phase were compared to the range of scores 
in the baseline phase.  
Third, effect sizes were calculated to estimate the magnitude of change on 
primary and secondary outcome measures across all participants during the treatment and 
follow-up phases using a d-statistic specifically developed for SCED studies with 
multiple baseline designs (d-Hedges-Pustejovky-Shadish or DHPS; Hedges, Pustejovsky, 
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& Shadish, 2013). Unlike Cohen’s d, this d-statistic incorporates corrections for small 
sample sizes as well as autocorrelation of data, two conditions relevant to SCED data 
(Shadish et al., 2014). Another advantage of this statistic is that it uses the same metric as 
effect sizes commonly reported in larger, between-subjects designs, therefore results from 
SCED studies can be directly compared to larger treatment trials. Effect sizes and 
variances were calculated using the DHPS effect size SPSS macro found on the 
developer’s website (Shadish, 2015). After obtaining a value of d, 95% confidence 
intervals (CI) were calculated using the following formula: d +/- 1.96* srqt(Var). An 
effect size was considered statistically significant at p < .05 if the CI did not include zero. 
Results were interpreted using conservative guidelines of 0.2, 0.5, and 0.8 corresponding 
with small, medium, and large effects, respectively (Cohen, 1988). Effect sizes were 
calculated to estimate the magnitude of change between baseline and treatment phases as 
well as baseline and follow-up phases. 
To evaluate the hypothesis that changes in positive affect would precede 
improvements in disorder specific symptoms, weekly data from primary DASS subscale 
scores and PANAS PA subscale scores were plotted together on graphs for each 
participant and visually inspected for evidence of temporal patterns of change. For 
example, this hypothesis would be supported if visual changes in positive affect preceded 
visible changes in DASS symptoms corresponding to principal disorder diagnoses. 
To reduce patient burden, certain secondary outcome measures were only 
administered pre- and post-intervention, or before Session 1 and before the post-treatment 
session respectively. Changes in pre- and post-treatment outcome measures (e.g., CSR, 
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dispositional positive emotions, affective styles, trait anger) were evaluated using two-
tailed, paired-samples t-tests with a 95% confidence interval. For all significant t values, 
Cohen’s d statistic was calculated to estimate effect size. Effect sizes were interpreted 
using Cohen’s guidelines as mentioned above.  
Daily, single-item ratings of depression symptoms, anxiety symptoms, and 
positive emotions completed during baseline and treatment phases were analyzed using 
visual inspection. Due to the restricted range of daily data scores, data were collapsed 
into weekly averages for each participant to introduce adequate variability for visual 
analysis. These collapsed weekly scores were then graphed and labeled by baseline week 
(B1, B2, etc.) and treatment session (T1, T2, etc.), with each time point representing the 
day of that time point and following week. The level, slope, and stability of daily data 
symptoms in each phase were examined to detect changes in symptoms following the 
introduction of the study intervention. 
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Results 
Primary Outcomes 
To conduct visual inspection, weekly scores for each study completer (n = 9) were 
graphed for each of the primary outcome measures (DASS-D or DASS-S, PANAS PA) 
during baseline (B), treatment (T), and follow-up (F) (See Figures 1-2).  In each outcome 
figure, the three columns of graphs from left to right respectively depict data 
corresponding to participants with a principal diagnosis of a depressive disorder, GAD, 
and social anxiety.  
Depression and Anxiety. As seen in Figure 1, baseline DASS outcome data were 
either stable or increasing for all participants except P2. However, P2’s scores 
demonstrated a decreasing slope that was deemed unreliable due to having a baseline RCI 
less than |1.86|. During the treatment phase, visual inspection revealed that five 
participant’s scores (P5, P11, P8, P4, P7) demonstrated decreasing slopes and four had 
visibly lower levels of symptom scores (P5, P11, P8, P7), which indicated improvement 
in depression (P5, P11) and anxiety (P4, P8, P7) symptoms following the introduction of 
the intervention. Despite P4’s decreasing slope of treatment DASS scores, the magnitude 
and range of her treatment scores did not appear significantly different from baseline 
scores, hence these improvements were unlikely to reflect meaningful changes. The range 
of P7’s treatment scores did not appear visually distinct from the range of her baseline 
scores until the final treatment session, which suggests a possible latency effect of the 
intervention. Of these five participants who demonstrated visible improvement during the 
treatment phase, quantitative analyses revealed that only P11’s change in DASS 
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Figure 1. Primary DASS Depression and DASS Stress outcomes. Individual primary 
DASS outcomes are plotted for each participant weekly throughout baseline (B), before 
each treatment session (T), and during post-treatment (F1), 2- and 4-week follow-up (F2 
and F3). Mean phase scores for each participant are represented by dotted lines. DASS 
Depression subscales scores are plotted for participants P2, P5, and P11; DASS Stress 
subscale scores are plotted for all other participants. DASS = Depression Anxiety Stress 
Scales; P = participant. 
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Table 3. Reliable Change Indices (RCI) and Percentage of Nonoverlapping Data (PND) 
for Primary Outcome Measures  
 DASS1  
RCI 
DASS1 
% PND 
PANAS – 
PA 
RCI 
PANAS – 
PA 
% PND 
PANAS – 
NA 
RCI 
PANAS – 
NA 
% PND 
P1 
Baseline 
Baseline-Tx 
Baseline-FU 
 
1.95 
-0.63 
-0.50 
 
-- 
33.33% 
0% 
 
-0.55 
-0.16 
-0.01 
 
-- 
0% 
0% 
 
-1.34 
-0.27 
-0.41 
 
-- 
33.33% 
66.67%* 
P2 
Baseline 
Baseline-Tx 
Baseline-FU 
 
-1.20 
0.13 
-1.20 
 
-- 
0% 
66.67% 
 
-0.92 
-0.86 
-0.49 
 
-- 
66.67%- 
0% 
 
-0.34 
-0.88 
-1.88 
 
-- 
100%** 
100%* 
P4 
Baseline 
Baseline-Tx 
Baseline-FU 
 
0.82 
-0.72 
-2.85* 
 
-- 
16.67% 
100%** 
 
0.00 
-0.70 
-1.04 
 
-- 
50%^ 
66.67%^ 
 
0.34 
-0.88 
-1.88 
 
-- 
66.67%* 
100%** 
P5 
Baseline 
Baseline-Tx 
Baseline-FU 
 
0.80 
-1.65 
-2.58* 
 
-- 
83.33%** 
100%** 
 
-0.37 
0.48 
0.88 
 
-- 
66.67* 
100%* 
 
0.84 
-1.13 
-1.96* 
 
-- 
66.67* 
100%* 
P7 
Baseline 
Baseline-Tx 
Baseline-FU 
 
-0.78 
-0.91 
-0.78 
 
-- 
66.67%+ 
66.67% 
 
0.37 
0.98 
-0.06 
 
-- 
100%* 
33.33% 
 
-0.34 
-0.17 
-0.39 
 
-- 
33.33% 
33.33% 
P8 
Baseline 
Baseline-Tx 
Baseline-FU 
 
1.24 
-1.65 
-1.79 
 
-- 
88.33%* 
100%* 
 
-0.55 
0.31 
0.67 
 
-- 
33.33% 
33.33% 
 
0.34 
-0.81 
-0.95 
 
-- 
100%** 
100%* 
P10 
Baseline 
Baseline-Tx 
Baseline-FU 
 
1.56 
0.83 
0.83 
 
-- 
50%- 
66.67%- 
 
1.65 
-0.33 
-0.35 
 
-- 
0% 
0% 
 
0.67 
-0.07 
-0.66 
 
-- 
0% 
66.67+ 
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P11 
Baseline 
Baseline-Tx 
Baseline-FU 
 
0.00 
-5.67* 
-8.20* 
 
-- 
100%** 
100%** 
 
-0.92 
3.63* 
5.50* 
 
-- 
100%** 
100%** 
 
1.84 
-3.21* 
-4.91* 
 
-- 
83.33%* 
100%** 
P12 
Baseline 
Baseline-Tx 
Baseline-FU 
 
1.65 
0.07 
-0.96 
 
-- 
0% 
33.33% 
 
0.00 
-0.48 
-0.60 
 
-- 
83.33^^ 
66.67- 
 
0.34 
-0.39 
-0.80 
 
-- 
50%+ 
100%* 
Note. Baseline-Tx = RCI and PND calculated from outcome scores in the treatment phase 
compared with baseline phase scores. Baseline-FU = RCI and PND calculated from 
outcome scores in the follow-up phase compared with baseline phase scores. DASS = 
Depression Anxiety Stress Scales; PANAS-PA = Positive and Negative Affect Scale, 
Positive Affect subscale; PANAS-NA = Positive and Negative Affect Scale. 
1DASS Depression subscale was analyzed for P2, P5, and P11, and DASS Stress subscale 
was analyzed for all other participants. 
** = significant improvement at p < .01 level; * = significant improvement at p < .05 
level; + = improvement at p < 0.1; ^^ = significant worsening at p < .01 level; ^ = 
significant worsening at p < .05 level; - = worsening at p < 0.1 
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symptoms was deemed clinical reliable. However, significant PND with baseline scores 
(a less conservative measure of symptom change) was observed for P5, P8, and P11 (see 
Table 3).  
During the follow-up phase, visual analysis revealed that DASS scores either 
continued to decrease (P5, P4) or remained at a stable, lower level than baseline scores 
(P8, P11) for four participants. Although P2’s DASS-D scores at follow-up visually 
demonstrated a decreasing slope and lower level than baseline scores, quantitative 
analyses produced non-significant PND and RCI values for these changes. Although P4’s 
DASS scores did not significantly improve during the treatment phase, during follow-up 
they appeared at a significantly lower level than either her baseline or treatment scores. 
This change in P4’s scores suggests stable improvement in anxiety symptoms during the 
follow-up phase. Per quantitative analyses, significant PND between baseline and follow-
up DASS scores were observed for four participants (P5, P11: depression; P4, P8; 
anxiety). Of these participants, three (P4, P5, and P11) were found to have clinically 
reliable improvement in DASS subscales corresponding to their principal diagnoses 
during the follow-up phase.  
Three participants showed no reliable pattern of changes during the treatment 
phase. P12’s graphs (P12) showed no visually discernable changes in the level of scores 
between baseline and treatment phases; however, the slope of DASS-S scores appeared to 
improve (become less steep) during treatment. By the follow-up phase, the level and 
slope of her scores appeared mildly improved compared with baseline; however, these 
changes were not reliable. P1’s data showed an immediate sharp reduction in DASS 
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symptoms following Session 1 of the intervention; however, her scores were highly 
variable during the treatment phase, and average appeared to overlap with the range of 
her baseline scores. Therefore, the intervention did not appear to exert a reliable effect on 
P1’s DASS symptoms. P10’s DASS data showed an initial decreasing slope after the first 
two sessions of treatment, then a consistently higher level of scores that remained stable 
following Session 3 of treatment through the end of the follow-up period.  Both visual 
and quantitative analyses revealed that the changes observed in P10’s treatment and 
follow-up DASS scores were neither significant nor clinically reliable.  
In summary, visual inspection revealed that 4 of the 9 participants showed 
improvements in primary DASS symptoms corresponding to their principal diagnoses 
during treatment, and a fifth visibly improved during the follow-up period. Three of these 
participants had significant PND compared to baseline scores during treatment and 
follow-up, and two (both with principal depression disorders) showed clinically reliable 
change per RCI analyses. Only one participant showed increased anxiety during 
treatment; however these changes were not clinically reliable. 
Positive Affect. On the Positive Affect (PA) scale of the PANAS, visual analysis 
revealed that outcome data were either stable or decreasing for all participants during the 
baseline period, except P10 (see Figure 2). P10’s scores showed an increasing slope that 
would suggest spontaneous improvement in PA; however, quantitative analyses revealed 
that this change was unreliable (see Table 3).  
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Figure 2. Primary PANAS Positive Affect outcomes. Individual primary PANAS Positive 
Affect subscale outcomes are plotted for each participant weekly throughout baseline (B), 
before each treatment session (T), and during post-treatment (F1), 2- and 4-week follow-
up (F2 and F3). Mean phase scores for each participant are represented by dotted lines. 
PANAS-PA = Positive and Negative Affect Scales, Positive Affect Scale; P = participant
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During treatment, visual analysis revealed a pronounced increasing slope and 
change in magnitude of PA for P11. In addition, two participant’s scores (P5, P7) showed 
a mildly increasing slope and slightly higher magnitude of scores compared to baseline. 
Quantitative analyses revealed significant PND between treatment and baseline for these 
three participants; however, only P11’s increases in PA during the treatment phase were 
clinically reliable (see Table 3). During the follow-up phase, P5 and P11’s score 
remained stable at higher levels than baseline, whereas P7’s scores returned to baseline 
levels. These visual observations were corroborated by quantitative analyses, which 
showed significant PND between follow-up and baseline phases for P5 and P11, but not 
P7. Again, only P11’s PA scores during follow-up indicated clinically reliable changes 
from baseline levels.  Although P8’s treatment PA scores showed improvement in the 
rate of symptom change via observed slope (going from a decreasing baseline to roughly 
horizontal treatment slope), there were no discernable or quantitative differences in the 
level of PA scores across baseline, treatment, and follow-up phases.  
In contrast to participants with visible improvements in PA scores during 
treatment and follow-up phases, visual analysis indicated a slightly lower magnitude of 
PA scores during the treatment phase for P2 and P4 (despite an increasing slope for P4), 
as well as changes in observed slopes for P12 (from horizontal baseline to decreasing 
treatment slope) and P10 (from increasing baseline to decreasing treatment slope) that 
indicated decreases in PA during treatment. Of these four participants, only P4 and P12 
had significant PND between treatment and baseline phases, and none of these visually 
observed changes were deemed clinically reliable. At follow-up, the magnitude of PA 
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scores for P2 and P12 appeared to return to baseline levels, whereas P4’s scores appeared 
to remain stable at a lower magnitude than baseline. P4’s PA scores at follow-up showed 
significant PND with baseline scores, yet not at a clinically reliable level. Despite P10’s 
changes in slope during treatment, her treatment and follow-up scores remained within 
the range of baseline PA scores and were not deemed clinically reliable. Finally, both 
visual and quantitative analyses revealed no observable changes in either slope or level of 
PA scores across baseline, treatment, and follow-up phases for P1.  
In summary, visual inspection revealed that four participants showed 
improvements in PA during treatment, and these changes remained stable throughout the 
follow-up period for three individuals. PND analyses confirmed significant nonoverlap 
with baseline scores in the expected direction (increases) for two participants, and P11’s 
changes were clinical reliable. On the other hand, three participants showed decreasing 
PA during treatment, with one individual remaining at stable, lower PA levels during 
follow-up. Contrary to prediction, one participant showed significant PND of treatment 
scores below the baseline range of PA scores; however, this change was not reliable.    
Secondary Outcomes  
Negative Affect. On the Negative Affect (NA) scale of the PANAS, all 
participants demonstrated stable or worsening NA at baseline, with the exception of 
participant P1 (see Figure 3). Although P1’s scores markedly decreased between B0 and 
B1, they remained stable throughout the rest of the 6-week baseline, and her overall 
baseline phase changes in NA were not clinically reliable (see Table 3).  
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Figure 3. PANAS Negative Affect outcomes. Individual PANAS Negative Affect subscale 
outcomes are plotted for each participant weekly throughout baseline (B), before each 
treatment session (T), and during post-treatment (F1), 2- and 4-week follow-up (F2 and 
F3). Mean phase scores for each participant are represented by dotted lines. PANAS-NA 
= Positive and Negative Affect Scales, Negative Affect; P = participant. 
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Visual analysis revealed decreases during the treatment phase in the magnitude of 
NA scores for four participants (P2, P5, P11, and P4), with decreasing slopes occurring 
for three of these participants (P5, P11, and P4). In addition, smaller decreases in mean  
analyses revealed significant PND between baseline and treatment phases for all five of 
these participants, or 56% of treatment completers; however, only P11’s improvements in 
NA were deemed clinically reliable (see Table 3). During the follow-up period, NA 
appeared to remain at stable, lower levels than baseline for the six participants who 
showed improvements during treatment (P2, P5, P11, P8, P12, P4). Seventy-eight percent 
of study completers had significant PND between baseline and follow-up phases (P2, P5, 
P11, P8, P12, P4, and P1). Nevertheless, only two participants’ (P5 and P11) 
improvements in NA between baseline and follow-up were clinically reliable.   
Overall, visual inspection revealed evidence of clinical improvement in NA for 5 
participants during treatment and an additional 3 participants during the follow-up phase. 
These changes were corroborated by significant PND for 4 participants during treatment 
and 5 during follow-up. In addition, two participants showed clinically reliable change 
per RCI. Only one participant showed no improvements in NA during treatment or 
follow-up. 
State Anger. On the STAXI-2 State Anger Scale (SAS), outcome data in the 
baseline phase were either stable or increasing for all nine participants (see Figure 4). 
Four participants with marked increases in anger during baseline (P2, P5, P11, P7) 
showed relatively immediate changes in both the slope (decreasing or horizontal) and 
level (decreased) of 
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scores between baseline and treatment were found to be clinically reliable for P5. For 
participants P2 and P11, more than half of treatment scores fell below the range of their 
baseline scores. P2’s treatment gains were not statistically significant, but P11’s 
treatment scores showed significant PND with baseline scores and clinically reliable 
change. During the follow-up phase, treatment gains for three participants were either 
maintained (P5, P11) or further improved upon (P2) and deemed clinically reliable. P7’s 
modest treatment gains did not continue into the follow-up phase. 
In contrast, two participants showed some increases in SAS during the treatment 
phase. P12 showed a spike in state anger scores at Session 4, which she attributed to a 
work-related stressor. P10 showed a relatively stable baseline (with the exception of an 
unexplained spike in state anger scores at B1), followed by a visible increase in slope and 
level of state anger symptoms during treatment. For this participant, however, the range 
of anger scores observed during treatment and follow-up phases overlapped entirely with 
her (highly variable) baseline scores. There were no discernable changes or quantitative 
differences in slope or level of SAS scores across baseline, treatment, and follow-up 
phases for all three participants with a principal diagnosis of GAD (P8, P12, P4), as well 
as one participant with a principal diagnosis of social anxiety disorder (P1).  
Overall, visual inspection and quantitative analyses revealed the strongest 
treatment effects on state anger for the three participants with principal depression 
diagnoses. During treatment, two of these participants showed reliable changes in state 
anger, and by follow-up all three showed reliable change per RCI values.  
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Figure 4. Weekly STAXI-2 State Anger Scale outcomes. Individual STAXI-2 State Anger 
Scale outcomes are plotted for each participant weekly throughout baseline (B), before 
each treatment session (T), and during post-treatment (F1), 2- and 4-week follow-up (F2 
and F3). Mean phase scores for each participant are represented by dotted lines. STAXI-2 
= State Trait Anger Expression Inventory 2; P = participant. 
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Table 4. Reliable Change Indices (RCI) and Percentage of Nonoverlapping Data (PND) 
for Quality of Life, Functional Impairment, and State Anger Outcomes 
 Q-LES-Q  %PND SSS  %PND SAS %PND 
P1 
Baseline 
Baseline-Tx 
Baseline-FU 
 
0.51 
-0.90 
-0.81 
 
-- 
16.67 
33.33% 
 
0.36 
-0.05 
0.25 
 
-- 
0% 
0% 
 
0.00 
0.37 
0.07 
 
-- 
16.67% 
33.33% 
P2 
Baseline 
Baseline-Tx 
Baseline-FU 
 
0.68 
0.65 
0.80 
 
-- 
50% 
33.33% 
 
0.12 
-0.99 
-1.38 
 
-- 
100%** 
100%* 
 
2.10* 
-1.25 
-3.39* 
 
-- 
66.67+ 
100%* 
P4 
Baseline 
Baseline-Tx 
Baseline-FU 
 
0.68 
0.73 
3.26* 
 
-- 
50%* 
66.67%* 
 
0.48 
-0.02 
-0.96 
 
-- 
16.67% 
66.67* 
 
0.30 
-0.15 
-1.20 
 
-- 
0% 
33.33% 
P5 
Baseline 
Baseline-Tx 
Baseline-FU 
 
-1.87 
1.35 
3.08* 
 
-- 
66.67%* 
100%* 
 
-0.36 
-0.15 
-0.61 
 
-- 
50%+ 
100%* 
 
2.40* 
-2.06* 
-2.46* 
 
-- 
33.33% 
66.67+ 
P7 
Baseline 
Baseline-Tx 
Baseline-FU 
 
1.19 
0.51 
0.43 
 
-- 
33.33% 
33.33% 
 
0.24 
-0.28 
-0.16 
 
-- 
83.33+ 
33.33% 
 
3.29* 
-0.20 
-0.05 
 
-- 
0% 
0% 
P8 
Baseline 
Baseline-Tx 
Baseline-FU 
 
0.34 
0.23 
0.74 
 
-- 
50% 
66.67% 
 
0.00 
0.02 
0.00 
 
-- 
16.67% 
33.33% 
 
0.90 
-0.25 
-0.20 
 
-- 
0% 
0% 
P10 
Baseline 
Baseline-Tx 
Baseline-FU 
 
1.19 
2.11* 
2.11* 
 
-- 
83.33* 
100%* 
 
1.82 
1.51 
1.47 
 
-- 
100%^^ 
100%^ 
 
0.90 
0.62 
-0.08 
 
-- 
0% 
0% 
P11 
Baseline 
Baseline-Tx 
Baseline-FU 
 
-0.34 
5.99* 
6.76* 
 
-- 
100%** 
100%** 
 
1.09 
-1.80 
-3.40* 
 
-- 
83.33%** 
100%** 
 
2.99* 
-4.76* 
-6.76* 
 
-- 
83.33%* 
100%** 
P12 
Baseline 
 
2.04* 
 
-- 
 
-0.61 
 
-- 
 
0.30 
 
-- 
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Baseline-Tx 
Baseline-FU 
0.51 
0.31 
16.67% 
0% 
-0.39 
-0.63 
16.67% 
66.65+ 
0.18 
0.18 
16.67% 
0% 
       
Note. Baseline-Tx = RCI and PND calculated from outcome scores in the treatment phase 
compared with baseline phase scores. Baseline-FU = RCI and PND calculated from 
outcome scores in the follow-up phase compared with baseline phase scores. QLES-Q = 
Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form; SSS = 
Subjective Symptoms Scales; SAS = State Trait Anger Expression Inventory, State 
Anger Scale. 
** = significant improvement at p < .01 level; * = significant improvement at p < .05 
level; + = improvement at p < 0.1; ^^ = significant worsening at p < .01 level; ^ = 
significant worsening at p < .05 level; - = worsening at p < 0.1 
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Functional Impairment. Regarding functional impairment due to psychological 
symptoms, baseline SSS data were either stable (P2, P5, P8) or worsening (P11, P4, P7, 
P10) for the majority of participants (see Figure 5). Participant P12 showed a steady 
decrease in functional impairment across baseline, but this change was not clinically 
reliable (see Table 4). P1’s baseline data showed an increasing trend through Week 4, 
then a sharp decreasing trend in the last two weeks of the baseline phase; however, the 
last two weeks of baseline data fell within the range of other baseline scores and her 
baseline change in functional impairment was not clinically reliable.  
 During the treatment phase, two participants (P2, P11) showed clear changes in 
the slope following the introduction of the study intervention (from increasing baseline to 
decreasing treatment slopes), as well as lower SSS symptoms compared to baseline. 
These two participants’ SSS scores demonstrated significant PND between treatment and 
baseline phases; however, these changes were not clinically reliable (see Table 4). 
Similarly, P7 and P12’s SSS scores showed small improvements in symptoms magnitude 
compared to baseline, but quantitative analyses indicated significant overlap with 
baseline scores and non-significant RCIs. Two participants (P4, P5) demonstrated no 
changes in the magnitude of functional impairment during the treatment phase, but lower 
levels of functional impairment at follow-up. Of note, P4’s scores showed high variability 
during treatment; initially increasing in the first three weeks of treatment, sharply 
decreasing after Week 3 of the intervention, then stabilizing at a similar level to baseline 
scores. Clinical improvement was observable via a decreasing slope during follow-up and 
mean SSS level that was visibly lower than baseline. Across all participants, mean phase 
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Figure 5. Weekly functional impairment (SSS) outcomes. Individual SSS outcomes are 
plotted for each participant weekly throughout baseline (B), before each treatment session 
(T), and during post-treatment (F1), 2- and 4-week follow-up (F2 and F3). Mean phase 
scores for each participant are represented by dotted lines. SSS = Subjective Symptoms 
Scales; P = participant.
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scores visually appeared lower than baseline scores for P2, P5, P11, and P4. Although all 
four of these participants had significant PND between follow-up and baseline phases, 
only P11’s scores at follow-up indicated clinically reliable decreases in functional 
impairment compared with baseline (see Table 4).  
In contrast to participants who showed various degrees of decreased functional 
impairment during treatment and / or follow-up phases, two participants (P8, P1) 
demonstrated no visibly discernable or quantitative changes in the slope or magnitude of 
functional impairment across baseline, treatment, and follow-up phases. In addition, 
P10’s mean level of functional impairment at treatment appeared higher than her baseline 
level, which indicates worsening functional impairment during treatment. Her functional 
impairment also remained at a stable, higher level than baseline during the follow-up 
period. These observations were partially corroborated by significant PND during 
treatment and follow-up phases compared to baseline. Nonetheless, her treatment and 
follow-up changes were not clinically reliable (see Table 4). Additionally, both the 
baseline and treatment phases for P10 showed increasing slopes. Therefore, increases in 
SSS during treatment may represent a continuation of worsening functional impairment 
observed during the baseline phase and are likely not attributable to the study 
intervention. Furthermore, P10’s functional impairment scores during treatment changed 
at an overall slower rate than increases observed during baseline. They also stabilized 
after Session 3 of treatment and remained at roughly that level throughout the follow-up 
phase. Hence, the study intervention may have slowed P10’s natural progression towards 
greater functional impairment.  
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In summary, visual inspection revealed that functional impairment due to disorder 
symptoms decreased for three participants during the treatment phase, with 
improvements remaining stable through follow-up for two participants. By the follow-up 
phase, 5 participants showed decreased functional impairment; one of whom also showed 
clinically reliable change. One participant’s data revealed worse functional impairment 
during baseline and follow-up phases compared to baseline per visual inspection and 
PND analysis. However, given the steep increasing slope of her baseline scores, this 
participant’s relatively stable symptoms during treatment and follow-up may actually 
reflect a possible buffering effect of the intervention against the natural course of her 
illness. 
Quality of Life. On the QLES-Q-SF, baseline data were either stable (P8, P7) or 
worsening (P5, P4, P11) for the majority of participants (see Figure 6). Baseline data for 
P11 and P4 showed high variability, but overall demonstrated a slightly decreasing slope 
across the phase. Although mildly increasing slopes were observed for P1, P2, and P10 
during baseline, these changes were deemed unreliable due to having baseline RCIs less 
than |1.86| (see Table 4). However, P12’s observed increases during the baseline period 
were clinically reliable. Therefore, it can be inferred that her baseline quality of life 
improved independently, and further improvements that occurred during treatment cannot 
be attributed solely to the study intervention. 
 During the treatment phase, three participants (P5, P10, P11) demonstrated visible 
improvements in quality of life compared to baseline scores, as evidenced by changes in 
slope (P5, P11; decreasing baseline to increasing treatment slope) and higher magnitude 
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of treatment scores (P5, P11, P10). P4’s quality of life scores dropped below baseline 
levels after Session 1 of the study intervention, then steeply increased to levels above her 
baseline range after Session 4. Although her mean treatment score was not significantly 
different from her mean baseline score due to high treatment score variability, she had 
significant PND between baseline and treatment phases. Likewise, P5, P10, and P11 had 
significant PND between baseline and treatment phases. Nonetheless, only two 
participants (P10 and P11) demonstrated clinically reliable improvements of quality of 
life during the treatment phase.   
  During the follow-up phase, treatment gains were either maintained (P10, P11) or 
further improved upon (P5, P4) for four participants. Quantitative analyses confirmed 
that follow-up scores for these four participants showed significant nonoverlap with 
baseline scores and represented clinically reliable improvement (See Table 4). 
 Two participants showed only isolated periods of visible change in quality of life 
during the treatment phase. For example, P2 showed initial improvements in quality of 
life, then a sharp decline following Session 4 (a pattern also observed in P5 and P10). On 
the other hand, P8 demonstrated initial worsening in quality of life, following by a 
noticeable improvement after Session 5. For both of these participants, changes in quality 
of life did not stabilize during treatment or follow-up phases at a level that differed 
significantly from baseline scores. In addition, no visually discernable or quantitative 
changes in the magnitude or slope of quality of life data were observed across baseline, 
treatment, or follow-up phases for the remaining two participants with principal social 
anxiety disorder diagnoses (P1, P7).  
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Figure 6. Weekly quality of life (Q-LES-Q-SF) outcomes. Individual Q-LES-Q-SF 
outcomes are plotted for each participant weekly throughout baseline (B), before each 
treatment session (T), and during post-treatment (F1), 2- and 4-week follow-up (F2 and 
F3). Mean phase scores for each participant are represented by dotted lines. Q-LES-Q-SF 
= Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form; P = 
participant. 
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Overall, visual analysis revealed increases in quality of life for four participants, 
which were either maintained or further improved upon during the follow-up period. Of 
these participants, two showed clinically reliable improvements during treatment and all 
four showed clinically reliable improvements by follow-up. No participants showed 
deterioration in quality of life scores.  
Mindfulness. Weekly scores for four subscales of the FFMQ-15 (Describing, Acting 
with Awareness, Nonjudging of Inner Experiences, and Nonreactivity to Inner 
Experiences) were plotted for all participants and underwent both visual inspection and 
quantitative analyses. On the Describing subscale, only P4’s data showed a clear pattern 
of improvement during treatment. Her Describing scores remained at stable, higher-than-
baseline levels during the follow-up phase, but neither her treatment nor follow-up 
symptom changes were clinically reliable (see Table 5). While P8 showed a decreasing 
slope of Describing scores during treatment, these changes were also not clinically 
reliable. 
On the Acting with Awareness (Awareness) subscale, two participants (P2 and 
P11) showed visible improvements during the treatment phase as evidenced by changes 
in slope (increasing) and a higher magnitude of treatment scores compared to baseline 
(see Figure 8). In addition, two participants showed initial changes in Awareness scores 
following Session 1 (P7 showed an initial increase and P5 showed an initial decrease); 
however, their scores returned to baseline levels within the treatment phase. Only P11 
showed clinically reliable changes in Awareness scores during the treatment or follow-up 
phases (see Table 5). 
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Figure 7. Weekly FFMQ-15 Describing subscale outcomes. Individual Describing 
subscale outcomes from the FFMQ-15 are plotted for each participant weekly throughout 
baseline (B), before each treatment session (T), and during post-treatment (F1), 2- and 4-
week follow-up (F2 and F3). Mean phase scores for each participant are represented by 
dotted lines. FFMQ-15 = Five Factor Mindfulness Questionnaire, 15-item version; P = 
participant. 
  
Table 5. Reliable Change Indices (RCI) and Percentage of Nonoverlapping Data (PND) for selected subscales of the FFMQ-15 
 Describing  %PND Act with 
Awareness  
%PND Nonjudging  %PND Nonreactive %PND 
P1 
Baseline 
Baseline-Tx 
Baseline-FU 
 
0.61 
0.03 
-0.07 
 
-- 
0% 
16.67% 
 
-0.78 
-0.26 
-0.13 
 
-- 
16.67% 
0% 
 
0 
0.06 
0 
 
-- 
0% 
0% 
 
1.12 
0.37 
0.87 
 
-- 
0% 
0% 
P2 
Baseline 
Baseline-Tx 
Baseline-FU 
 
0.30 
0.26 
0.30 
 
-- 
33.33% 
66.67% 
 
-0.78 
0.72 
1.57 
 
-- 
66.67%+ 
100%* 
 
1.15 
0.64 
0.76 
 
-- 
66.67%+ 
66.67% 
 
-0.37 
0.19 
-0.50 
 
-- 
0% 
33.33% 
P4 
Baseline 
Baseline-Tx 
Baseline-FU 
 
0.00 
0.76 
0.91 
 
-- 
83.33%** 
100%** 
 
-0.39 
-0.30 
0.35 
 
-- 
0% 
33.33% 
 
0.76 
0.68 
2.15* 
 
-- 
66.67%* 
100%** 
 
-1.12 
0.68 
0.50 
 
-- 
16.67% 
0% 
P5 
Baseline 
Baseline-Tx 
Baseline-FU 
 
0.00 
0.23 
0.28 
 
-- 
16.67% 
0% 
 
0.00 
-0.08 
0.31 
 
-- 
16.67% 
33.33% 
 
1.53 
0.38 
0.51 
 
-- 
16.67% 
66.67%+ 
 
-0.75 
1.21 
2.01* 
 
-- 
83.33%** 
100%* 
P7 
Baseline 
Baseline-Tx 
Baseline-FU 
 
-0.61 
0.30 
0.10 
 
-- 
33.33% 
0% 
 
0.00 
0.78 
1.18 
 
-- 
66.67% 
100%+ 
 
0 
0.70 
0.13 
 
-- 
66.67% 
33.33% 
 
0 
0.44 
0.50 
 
-- 
50% 
100%+ 
P8 
Baseline 
Baseline-Tx 
Baseline-FU 
 
-0.30 
-0.30 
-0.30 
 
-- 
16.67% 
66.67% 
 
0.00 
0.26 
-0.39 
 
-- 
33.33% 
33.33% 
 
1.15 
0.45 
0 
 
-- 
33.33% 
0% 
 
-1.49 
0.25 
0 
 
-- 
16.67% 
0% 
P10 
Baseline 
 
-0.91 
 
-- 
 
0.39 
 
-- 
 
-0.38 
 
-- 
 
1.12 
 
-- 
  
Baseline-Tx 
Baseline-FU 
-0.12 
-0.53 
0% 
33.33% 
-0.48 
-0.42 
33.33% 
33.33% 
-0.56 
-0.43 
66.67%^ 
33.33% 
0.47 
0.22 
33.33% 
33.33% 
P11 
Baseline 
Baseline-Tx 
Baseline-FU 
 
0.91 
0.13 
0.13 
 
-- 
0%C 
0%C 
 
-1.18 
2.39* 
3.96* 
 
-- 
83.33%** 
100%** 
 
-1.15 
3.11* 
3.87* 
 
-- 
100%** 
100%** 
 
-1.49 
1.80 
1.99* 
 
-- 
83.33%** 
100%** 
P12 
Baseline 
Baseline-Tx 
Baseline-FU 
 
-0.30 
-0.06 
-0.06 
 
-- 
0% 
0% 
 
0.00 
-0.40 
-0.47 
 
-- 
0% 
0% 
 
0.38 
-0.52 
-0.84 
 
-- 
83.33%^^ 
100%^^ 
 
-0.37 
0.44 
0.75 
 
-- 
0% 
0% 
Note. Baseline-Tx = RCI and PND calculated from outcome scores in the treatment phase compared with baseline phase scores. Baseline-
FU = RCI and PND calculated from outcome scores in the follow-up phase compared with baseline phase scores. FFMQ-15 = Five Facet 
Mindfulness Questionnaire, 15-item version; Describing = FFMQ-15 Describing subscale; Act with Awareness = FFMQ-15 Acting with 
Awareness subscale; Nonjudging = FFMQ-15 Nonjudging of Inner Experience subscale; Nonreactive = FFMQ-15 Nonreactivity to Inner 
Experience subscale. 
** = significant improvement at p < .01 level; * = significant improvement at p > .05 level; + = improvement at p < 0.1; ^^ = significant 
worsening at p < .01 level; ^ = significant worsening at p < .05 level- = worsening at p < 0.1 
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On the Nonjudging of Inner Experiences (Nonjudging) subscale, three 
participants showed increases in the mean level of scores during the treatment phase (P4, 
P7, and P11; see Figure 9); however, only P11’s changes were clinically reliable (see 
Table 5). Scores continued to improve for P4 and P11 during the follow-up phase and 
reached statistical significance for P4. For P7, however, treatment gains were not 
maintained during the follow-up period. Although two participants (P10 and P12) showed 
decreased magnitude of average scores during treatment, only P12’s scores showed 
significant PND compared to baseline. Despite this trend towards deterioration in 
Nonjudging skills, neither P10 nor P12’s changes during treatment or follow-up phases 
were clinically reliable.  
Finally, on the Nonreactivity to Inner Experiences (Nonreactivity) subscale, four 
participants showed visible changes in the rate of symptom change between the baseline 
(decreasing slopes) and treatment phases (increasing slopes for P4, P5, and P11; 
horizontal slope for P8; see Figure 10). All participants’ treatment scores either remained 
at a consistent level with baseline or showed small increases from baseline levels. For 
two participants (P5 and P11), treatment scores showed significant PND with baseline 
scores (see Table 5). Despite P11’s trend towards clinically reliable change during 
treatment (RCI = 1.80), no participants’ data showed statistically significant change 
during treatment. During the follow-up phase, P5 and P11’s treatment gains remained 
stable at clinically reliable levels compared with baseline. It is also worth noting that 
despite not reaching the threshold of clinical reliability, P7’s follow-up Nonreactivity 
scores showed 100% PND with her baseline scores. 
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Figure 8. Weekly FFMQ15 Acting with Awareness subscale outcomes. Individual Acting 
with Awareness subscale outcomes from the FFMQ15 are plotted for each participant 
weekly throughout baseline (B), before each treatment session (T), and during post-
treatment (F1), 2- and 4-week follow-up (F2 and F3). Mean phase scores for each 
participant are represented by dotted lines. FFMQ15 = Five Factor Mindfulness 
Questionnaire, 15-item version; P = participant. 
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Figure 9. Weekly FFMQ-15 Nonjudging of Inner Experience Subscale Outcomes. 
Individual Nonjudging of Inner Experience subscale outcomes from the FFMQ-15 are 
plotted for each participant weekly throughout baseline (B), before each treatment session 
(T), and during post-treatment (F1), 2- and 4-week follow-up (F2 and F3). Mean phase 
scores for each participant are represented by dotted lines. FFMQ-15 = Five Facet 
Mindfulness Questionnaire, 15-item version; P = participant. 
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Figure 10. Weekly FFMQ-15 Nonreactivity to Inner Experience Subscale Outcomes. 
Individual Nonreactivity to Inner Experience subscale outcomes from the FFMQ-15 are 
plotted for each participant weekly throughout baseline (B), before each treatment session 
(T), and during post-treatment (F1), 2- and 4-week follow-up (F2 and F3). Mean phase 
scores for each participant are represented by dotted lines. FFMQ-15 = Five Facet 
Mindfulness Questionnaire, 15-item version; P = participant. 
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Effect Sizes 
Standardized mean differences (d with 95% CIs) were calculated to estimate the 
overall magnitude of the intervention effect across participants. Means and standard 
deviations for all outcome variables across each study phase and d-statistics comparing 
treatment versus baseline and follow-up versus baseline scores are presented in Table 6. 
These effect sizes suggest that across all participants, the study intervention was 
associated with a significant, large increase in scores on the FFMQ subscale 
Nonreactivity to Inner Experience, medium decreases in DASS-D, DASS-A, and DASS-
S scores, and PANAS NA, medium increases in quality of life, small increases in the 
FFMQ subscale Nonjudging of Inner Experience, and small decreases in state anger 
scores. When comparing follow-up to baseline scores, the intervention was associated 
with large decreases in DASS scores, negative affect, and large increases in quality of 
life. Also at follow-up, medium-sized increases were observed in three FFMQ subscales 
(Nonjudging of Inner Experiences, Nonreacitivity to Inner Experiences, and Acting with 
Awareness), and a small increase in positive affect was observed. Medium-sized 
decreases were seen in functional impairment (SSS) and anger. 
Given that one participant (P11) showed large improvements that were not typical 
of the rest of the sample, these tests were re-conducted excluding P11. Results from these 
tests are presented in Table 7.  After removing P11 from effect size analyses, the 
intervention’s effect on PANAS NA during treatment remained significant and moderate 
in magnitude, whereas other significant treatment effects decreased in magnitude (i.e., 
DASS-D, DASS-S, FFMQ-Nonreactivity to Inner Experiences). Specifically, treatment 
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effects sizes for DASS-D and DASS-S subscales decreased from moderate to small in 
magnitude, and the effect of LKM on FFMQ-15 Nonreactivity decreased from large to 
moderate in magnitude. Furthermore, several of the treatment effect sizes no longer 
reached statistical significance (DASS-A, STAXI-SAS, FFMQ-Nonjudging of Inner 
Experiences, Q-LES-Q-SF). In other words, after eliminating P11 from analyses, the 
treatment no longer exerted significant effects on anxiety, state anger, the mindfulness 
facet Nonjudging of Inner Experiences, and quality of life.  
With P11’s data excluded from follow-up phase scores, the intervention no longer 
exerted significant effects on positive affect or certain mindfulness facets (i.e., Acting 
with Awareness, Nonjudging of Inner Experiences). In addition, the magnitude of effect 
sizes reduced from strong to moderate for quality of life (QLES-Q-SF) and anxiety 
(DASS-A) outcomes. Follow-up effect sizes remained significant, strong, and positive for 
negative affect (PANAS-NA), depression (DASS-D), and anxiety (DASS-S), as well as 
significant, moderate, and positive for state anger (STAXI-SAS), functional impairment 
(SSS), and the mindfulness facet Nonreactivity to Inner Experiences.  
 
 
  
Table 6 
 
Mean Summary Scores and Effect Sizes for all Outcomes (N = 9) 
 Baseline Treatment Follow-up 
                        M (SD) M (SD) dtx     [95% CI] M (SD)   dfu [95% CI] 
DASS-D 19.64 (11.07) 12.19 (7.46) 0.63* [0.24, 1.02] 8.81  (6.87) 0.90* [0.38, 1.42] 
DASS-A 12.89 (7.76)  8.78 (5.02) 0.50* [0.11, 0.89] 6.00 (4.62) 0.88* [0.40, 1.36]  
DASS-S 
PANAS-PA 
PANAS-NA 
STAXI-SAS 
FFMQ-15 
  Describing 
  Act with Awareness 
  Nonjudging 
  Nonreactivity 
SSS 
Q-LES-Q-SF 
20.89 (8.62) 
21.61 (5.79) 
27.61 (8.21) 
24.66 (9.17) 
 
10.70 (2.56) 
7.57 (2.71) 
9.07 (3.88) 
7.36 (2.37) 
3.59 (1.52) 
51.66 (8.76) 
15.74 (6.70) 
23.20 (6.72) 
21.43 (5.23) 
21.33 (5.00) 
 
10.87 (2.46) 
8.28 (2.02) 
10.98 (2.53) 
9.07 (1.77) 
3.09 (1.25) 
59.46 (12.35) 
0.62*
0.26 
0.77* 
0.35* 
 
0.16 
0.28 
0.40* 
0.81* 
0.26 
0.63* 
[0.23, 1.01] 
[-0.08, 0.60] 
[0.33, 1.21] 
[0.01, 0.69] 
 
[-0.04, 0.36] 
[0.00, 0.56] 
[0.12, 0.68] 
[0.42, 1.20] 
[-0.08, 0.60] 
[0.19, 1.07] 
11.85 (6.58) 
24.19 (8.05) 
17.74 (3.64) 
18.96 (2.57) 
 
10.70 (2.58) 
9.22 (2.23) 
11.33 (1.85) 
9.22 (2.31) 
2.49 (1.42) 
63.04 (12.46) 
1.05* 
0.35* 
1.18* 
0.61* 
 
0.10 
0.56* 
0.47* 
0.76* 
0.78* 
0.97* 
[0.50, 1.60] 
[0.07, 0.63] 
[0.56, 1.80] 
[0.22, 1.00] 
 
[-0.10, 0.30] 
[0.22, 0.90] 
[0.13, 0.81] 
[0.32, 1.20] 
[0.30, 1.26] 
[0.45, 1.49] 
Note. All effect sizes were calculated such that positive d values indicate the expected direction of change (e.g., decreases in 
disorder symptoms, increases in positive affect). DASS-D = Depression Anxiety Stress Scales, Depression subscale; DASS-A 
= Depression Anxiety Stress Scales, Anxiety subscale; DASS-S = Depression Anxiety Stress Scales, Stress subscale; PANAS-
PA = Positive and Negative Affect Scale, Positive Affect subscale; PANAS-NA = Positive and Negative Affect Scale, 
Negative Affect subscale; FFMQ-15 = Five Facet Mindfulness Questionnaire; SSS = Subjective Symptoms Scale; Q-LES-Q-
SF = Quality of Life Events Questionnaire, Short Form; STAXI = State Trait Anger Expression Inventory 2, State Anger 
Scale.  
* = significant improvement at p < .05. 
 
  
Table 7 
 
Adjusted Mean Summary Scores and Effect Sizes for all Outcomes (N = 8a) 
 Baseline Treatment Follow-up 
                        M (SD) M (SD) dtx     [95% CI] M (SD)   dfu [95% CI] 
DASS-D 15.68 (6.68) 12.13 (7.22) 0.48* [0.14, 0.82] 9.92 (6.63) 0.81* [0.29, 1.33] 
DASS-A 10.79 (6.55)  9.13 (5.05) 0.25 [-0.23, 0.73] 6.75 (4.45) 0.65* [0.06, 1.24]  
DASS-S 
PANAS-PA 
PANAS-NA 
STAXI-SAS 
FFMQ 
  Describing 
  Act with Awareness 
  Nonjudging 
  Nonreactivity 
SSS 
Q-LES-Q-SF 
18.05 (6.00) 
23.35 (4.58) 
24.89 (5.55) 
21.46 (5.74) 
 
9.97 (2.09) 
8.32 (2.25) 
10.05 (3.43) 
8.00 (1.99) 
3.10 (1.07) 
53.49 (7.50) 
15.83 (6.09) 
22.08 (5.39) 
21.25 (4.31) 
20.79 (4.51) 
 
10.35 (2.13) 
8.10 (1.88) 
10.85 (2.62) 
9.10 (1.82) 
3.08 (1.59) 
57.25 (11.15) 
0.46*
-0.09 
0.73* 
0.21 
 
0.19 
0.03 
0.18 
0.70* 
0.05 
0.36 
[0.07, 0.85] 
[-0.37, 0.19] 
[0.29, 1.17] 
[-0.13, 0.55] 
 
[-0.09, 0.47] 
[-0.25, 0.31] 
[-0.02, 0.38] 
[0.31, 1.09] 
[-0.23, 0.33] 
[-0.08, 0.80] 
13.33 (5.49) 
21.92 (5.27) 
18.38 (3.42) 
18.96 (2.77) 
 
10.17 (2.26) 
8.67 (1.66) 
11.00 (1.64) 
9.21 (2.50) 
2.73 (1.33) 
60.71 (11.19) 
0.90* 
-0.11 
1.21* 
0.56* 
 
0.11 
0.26 
0.22 
0.65* 
0.54* 
0.71* 
[0.35, 1.45] 
[-0.39, 0.17] 
[0.59, 1.83] 
[0.17, 0.95] 
 
[-0.17, 0.39] 
[-0.02, 0.54] 
[-0.06, 0.50] 
[0.21, 1.09] 
[0.10, 0.98] 
[0.23, 1.19] 
Note. aP11’s scores were excluded from all analyses. All effect sizes were calculated such that positive d values indicate the 
expected direction of change (e.g., decreases in disorder symptoms, increases in positive affect). DASS-D = Depression 
Anxiety Stress Scales, Depression subscale; DASS-A = Depression Anxiety Stress Scales, Anxiety subscale; DASS-S = 
Depression Anxiety Stress Scales, Stress subscale; PANAS-PA = Positive and Negative Affect Scale, Positive Affect subscale; 
PANAS-NA = Positive and Negative Affect Scale, Negative Affect subscale; FFMQ-15 = Five Facet Mindfulness 
Questionnaire; SSS = Subjective Symptoms Scale; Q-LES-Q-SF = Quality of Life Events Questionnaire, Short Form; STAXI 
= State Trait Anger Expression Inventory 2, State Anger Scale.  
* = significant improvement at p < .05. 
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Patterns of Symptom Improvement 
 A secondary study hypothesis predicted that changes in PA would precede 
changes in depression and anxiety symptoms, given that PA has been shown to broaden 
cognitive and behavioral responses to stress (Frederickson, 1998, 2001) and promote 
more adaptive emotion regulation strategies (Hofmann et al, 2012). In contrast to this 
hypothesis, graphic depictions of DASS main outcomes scores superimposed on positive 
affect scores (see Figure 11) revealed no evidence of changes in PA preceding changes in 
DASS scores. Instead, for participants who showed improvement in both outcomes, 
changes in these outcomes appeared to occur simultaneously during treatment and 
follow-up phases. 
Treatment Acceptability 
Nine out of ten participants (90%) who began the study intervention completed a 
full course of treatment and responded to all weekly follow-up questionnaires. One 
participant dropped out of treatment after three sessions of the study intervention, due to 
reported discomfort with completing written homework assignments and a stated desire 
to seek less structured psychotherapy. His level of baseline DASS-S scores did not appear 
to differ significantly from other participants’ scores per visual inspection; hence, his 
attrition does not appear to be related to differences in baseline clinical presentation. 
Scores on the credibility subscale of the CEQ indicate that study completers found the 
intervention highly credible (M = 6.96 out of 9, SD = 1.01).  
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Figure 11. Primary DASS and PANAS PA outcomes. Individual primary DASS and 
PANAS Positive Affect subscale outcomes are plotted for each participant weekly 
throughout baseline (B), before each treatment session (T), and during post-treatment 
(F1), 2- and 4-week follow-up (F2 and F3). Mean phase scores for each participant are 
represented by dotted lines. DASS Depression subscales scores are plotted for 
participants P2, P5, and P11; DASS Stress subscale scores are plotted for all other 
participants. DASS data are represented by black diamonds and connected within phases 
by black solid lines. PANAS PA data are represented by gray triangles and connected 
within phases by gray dotted lines. DASS = Depression Anxiety Stress Scales; P = 
participant. 
Time 
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Satisfaction with Treatment 
After completing the intervention, participants provided feedback on the 
treatment. Overall satisfaction with treatment was quantitatively measured using the 
CSQ-8. The range of possible scores on this questionnaire is 8 to 32, with higher scores 
indicating greater global satisfaction. Scores from the study completers indicated that 
participants were satisfied with the LKM intervention (M = 26.38, SD = 1.80) at a level 
consistent with normative outpatient clinical samples (Attkinsson & Greenfield, 2004). 
The range of total scores (24 – 30) also fell within one standard deviation of normative 
means, which indicates no large differential in treatment satisfaction within the study 
sample. Results from the CSQ-8 item measuring overall satisfaction with services 
indicated that participants were on average “mostly satisfied” (M = 3.25, SD = 0.43).  
Given that the CSQ-8 does not measure reactions to specific features of the 
intervention, participants also provided qualitative feedback by responding to open-ended 
questions assessing their overall impressions of the intervention, what they found most 
and least helpful, what they would change, and what they learned during treatment. Some 
common overall themes from these qualitative data included: gaining a better 
understanding of the self and/or one’s thinking processes (P1, P4, P10, P11, P12); 
learning to accept thoughts and emotions (P4, P7, P11, P12); reductions in worry and 
anxiety (P1, P11, P12), and increasing positive emotions towards the self or others (P8, 
P10). Responses identifying the most and least helpful treatment elements were highly 
varied and addressed: (1) structural components of treatment (session length), (2) 
treatment information format (meditation exercise, handouts, the use of technology), and 
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(3) specific intervention topics (e.g., hindrances to LKM, intent, specific LKM exercises). 
For example, four participants identified that the meditation practice within and outside 
of sessions was the most helpful part of treatment (P1, P5, P8, P12), and two participants 
indicated that the handouts, which provided psychoeducation or prompted the participant 
to reflect on intervention skills, were the most helpful (P7, P10). Two participants 
identified specific treatment topics as the most beneficial part of the intervention. 
Specifically, P11 identified the concept of intent and practice of setting an intention (i.e., 
mindfully generating a specific goal at the beginning of meditation practice) as the most 
beneficial, and P4 identified that learning about the hindrances to LKM (e.g., anger, 
attachment, aversion) was most helpful. Regarding feedback on the least helpful aspects 
of treatment, two participants identified the meditation logs (P4, P10), one participant 
reported that the sessions were too long (P7), and two participants identified specific 
meditation exercises (P11: LKM towards difficult person; P12: non-LKM mindfulness 
meditation exercises).  
Pre/Post-treatment Outcomes 
 Difference scores were generated for each participant on all outcome measures 
administered pre- and post-treatment during the study. Due to administrator error, post-
treatment scores on self-report questionnaires P8 were not available for analysis. To 
identify outliers in the distribution of difference scores for each measure, interquartile 
ranges (IQRs) were calculated. Values at or exceeding 1.5 IQRs below the first quartile 
or above the third quartile were identified as outliers and excluded from further analyses. 
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Next, paired-samples t-tests were calculated for each outcome variable. The results are 
presented in Table 8.  
 An examination of self-reported dispositional positive emotions (measured by the 
DPES) before and after the study intervention revealed only significant, small increases 
in amusement following the intervention, t(5) = 3.37, p < .05, d = 0.39. Contrary to 
hypotheses, all other DPES emotions, including love, compassion, and contentment, 
showed no significant changes post-treatment. Although non-significant, results 
regarding trait anger as measured by the STAXI trended toward improvement, t(7) = 
2.07, p = .08. Regarding an overall picture of changes in clinical severity of disorder 
symptoms, clinician-rated CSRs showed significant, large decreases following the study 
intervention, t(8) = 3.33, p = .01, d = 1.28. 
 It was predicted that LKM would positively impact adaptive emotion regulation 
styles. Indeed, participants showed significant, moderate improvements on the tolerating 
subscale of the of the ASQ following the study intervention, t(6) = 2.47, p < .05, d = 0.56. 
No significant changes in other affective styles were observed in this sample.  
Daily Data Analyses 
Participants were regularly reminded by the study therapist to complete daily 
symptoms surveys throughout treatment. As previously mentioned, daily data were 
collapsed into weekly average scores to facilitate visual inspection, then graphed for each 
participant (see Figure 12). Collapsed weekly scores represent all daily data points 
following each baseline week (e.g., B1, B2) or treatment session (e.g., T1, T2). The level, 
slope, and stability of daily data symptoms in each phase were visually analyzed and  
  
Table 8 
 
Mean Summary Scores and Effect Sizes for Pre- and Post-Treatment Outcomes 
 Pre-treatment Post-treatment    
Outcome M SD M SD t(df*) p d 
DPES        
Amusement 21.83 4.54 23.50 4.04    3.37a,b 0.020 0.39 
Awe 25.88 3.09 27.50 4.24 1.31 0.231  
Compassion 27.75 3.49 28.13 4.05 0.32 0.760  
Contentment 23.00 2.24 22.57 4.96  0.36a 0.732  
Joy 22.75 5.23 24.88 6.06  1.68a 0.248  
Love 23.43 5.26 24.14 6.15  0.67a 0.527  
Pride 22.88 2.59 24.63 3.62 0.83 0.433  
STAXI-2         
Trait Anger 20.63 3.66 18.5 1.77 2.07 0.077  
ASQ        
Concealing 30.00 6.23 28.75 4.83 0.58 0.583  
Adjusting 19.14 4.22 18.57 4.12  0.31a 0.766  
Tolerating 14.57 2.44 15.86 2.19  2.47a 0.049 0.56 
CSR 5.33 0.87 3.22 2.17  3.33c 0.010 1.28 
Note. DPES = Dispositional Positive Emotions Scales; STAXI-2 = State Trait Anger Expression Inventory; ASQ = Affective 
Styles Questionnaire; CSR = Clinical Severity Rating from the Anxiety and Related Disorders Interview Schedule for DSM-5. 
*df = 7 in all cases except for when a superscript letter appears, which denotes the following: a = P11’s outlier data were 
excluded from analysis, b = P2’s outlier data were excluded from analysis, c = all 9 participants’ data were included in analysis. 
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results are reported below. For each participant, daily data results were compared to 
results from weekly primary DASS and PANAS-PA scores in order to assess consistency 
of self-report scores across these measurement modalities. 
P2. P2’s collapsed daily data scores revealed an increasing baseline for depression 
symptoms, a stable baseline for positive emotions, and a decreasing baseline for anxiety 
symptoms. Following Session 1 of the study intervention, P2’s daily depression 
symptoms showed a decreasing slope and remained at a stable, lower level than baseline 
scores for the duration of treatment. In contrast, his positive emotion scores remained 
relatively stable with baseline scores for the duration of treatment. His anxiety scores also 
remained at a level similar to baseline scores until Sessions 6 and 7, when they continued 
to steadily decrease below the range of baseline scores. Due to the decreasing slope of 
daily anxiety symptoms observed during the baseline period, it is impossible to determine 
whether changes in anxiety symptoms during treatment were due to the effects of the 
intervention or the passing of time. In summary, P2’s collapsed daily data revealed 
significant changes in the daily experience of depression symptoms following the 
introduction of the study intervention. Positive emotion scores did not show meaningful 
changes during treatment, and changes in anxiety symptoms could not be reliably 
associated with treatment. While these daily data are consistent with weekly DASS-S and 
PANAS PA scores, the daily depression data show an earlier and more stable treatment 
response than DASS-D scores.  
P5. P5’s collapsed daily data scores revealed an increasing slope for baseline 
depression symptoms, stable baseline for anxiety symptoms, and decreasing slope for 
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Figure 12. Collapsed daily symptoms ratings during baseline and treatment phases. 
Completed daily depression, anxiety, and positive emotions ratings for each participant 
were collapsed into weekly mean symptom ratings and plotted. Collapsed ratings were 
plotted weekly during baseline (B) and for each week following treatment sessions (T1 – 
T7). Depression ratings are represented by black diamonds and connected within phases 
by black solid lines. Anxiety ratings are represented by gray circles and connected within 
phases by gray dotted lines. Positive emotions ratings are represented by light gray 
triangles and connected within phases by light gray solid lines. P = participant. 
Time 
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baseline positive emotions. During treatment, daily depression ratings showed a 
decreasing slope and remained at a stable, lower average level than baseline scores 
following Session 6. Daily positive emotion scores showed a similar trajectory of steady 
improvement (increasing slope) during treatment; however, positive emotion scores 
exceeded the range of baseline scores at an earlier point in treatment, following Session 
3. Daily anxiety ratings remained at a stable level and slope during the first four weeks of 
treatment (consistent with baseline scores), then sharply decreased after Session 5 to a 
stable, lower level than baseline scores. Taken together, these results suggest that the 
intervention was associated with meaningful increases in P5’s daily experience of 
positive emotion early in treatment, as well as meaningful decreases in his daily 
experience of depression and anxiety symptoms during the second half of treatment. 
Increases in positive emotions did not appear to precede noticeable changes in depression 
symptoms; however, both increases in positive emotions and decreases in depression 
symptoms appeared to precede daily anxiety symptoms by several weeks. P5’s collapsed 
daily depression and positive emotion scores during baseline and treatment were similar 
to his weekly DASS-D subscale and PANAS PA subscale scores. On the other hand, P5’s 
weekly DASS-A and DASS-S subscale scores showed larger decreases in anxiety, 
tension, and general negative affect and at an earlier point in treatment than his daily 
global anxiety ratings.  
P11. P11’s collapsed daily data scores revealed a steady worsening of depression, 
anxiety, and positive emotion symptoms during the baseline period, as evidenced by 
increasing depression and anxiety score slopes and a decreasing positive emotion score 
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slope. During treatment, slopes for depression and anxiety symptoms decreased sharply, 
which indicates significant improvement in these symptoms following the introduction of 
the study intervention. The level of depression scores fell below the range of baseline 
scores following Session 2, whereas anxiety and positive emotion scores did not appear 
to show improvement beyond the baseline range of scores until Session 3. Compared 
with P11’s weekly primary outcomes data, his daily depression ratings appeared to 
decrease at a faster rate and reach stability at “not at all” levels weeks before his weekly 
DASS-D scores showed such improvement. On the other hand, his daily positive emotion 
scores showed less consistent improvement and visually exceeded baseline levels one 
week later than weekly PANAS PA scores did. Both daily anxiety ratings and DASS-S 
subscale scores only appeared visually distinct from P11’s range of baseline scores by 
Session 3 (LKM toward friend). In summary, P11’s collapsed daily data scores revealed 
similar patterns of clinical improvement in depression, anxiety, and positive emotion 
symptoms as were observed in his weekly questionnaire scores. However, daily data 
scores revealed faster improvements in depression symptoms and slower improvements 
in positive emotions than did weekly scores. Changes in positive emotion scores did not 
precede changes in depression or anxiety scores, but rather changes in depression scores 
appeared to precede changes in positive emotion scores. 
P8. P8’s collapsed daily data revealed stable baselines for depression, anxiety, 
and positive emotion symptoms. During treatment, little visible change was observed in 
anxiety symptoms or positive emotions until Session 7, after which both ratings showed 
meaningful improvements compared to baseline scores. His daily experience of 
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depression symptoms showed an increasing slope during treatment and overall higher 
mean level of symptoms than baseline scores. However, his collapsed daily depression 
score decreased back to baseline levels following Session 7. Of note, Session 7 coincided 
with the end of P8’s final exam period. Compared with his weekly questionnaire scores, 
P8’s daily data revealed less improvement in general anxiety scores than improvements 
seen on the DASS-S subscale. In both daily and weekly self-report data, anxiety 
symptoms peaked around Session 5 of the study treatment, which coincided with the 
beginning of his final exams study period. His daily depression scores revealed a 
worsening of daily depression symptoms, whereas weekly DASS-D scores revealed 
steady improvements in depression symptoms during treatment. Daily and weekly ratings 
of positive emotions revealed little change in these symptoms during treatment.  
P12. P12’s collapsed daily data during baseline showed an increasing slope for 
anxiety symptoms, stable slope for positive emotions, and decreasing slope for 
depression symptoms, which indicates worsening anxiety, stable frequency of positive 
emotions, and some improvement in depression during baseline. Her daily depression 
scores appeared to sharply increase following the introduction of the study treatment and 
again following Session 4, which focused on cultivating metta towards the self. Overall, 
daily depression scores showed a decreasing slope during treatment, yet remained at a 
similar mean level as baseline symptoms. Visual analysis of anxiety symptoms during 
treatment revealed similar results; although the slope of anxiety symptoms decreased 
during treatment, the magnitude of these scores did not appear visually distinct from her 
range of baseline scores. P12’s positive emotions ratings during treatment demonstrated 
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roughly the same slope and magnitude as her baseline scores, and indicate no significant 
changes in positive emotion during treatment. These daily symptom ratings appear 
consistent with weekly questionnaire scores that showed no reliable symptom change in 
DASS-S, DASS-D, and PANAS PA scores during treatment. 
P4. P4’s collapsed daily data during baseline showed high variability across 
anxiety and depression scores; however, elevated scores for these variables during the 
week of B3 may be attributed to P4’s reported distress associated with Valentine’s Day. 
Taking this stressor into account, anxiety scores showed a stable baseline, depression 
scores showed a slightly increasing baseline. Her positive emotions ratings appeared 
stable during baseline. During treatment, daily anxiety scores exceeded the range of 
baseline scores during the week of Session 1 and were consistent with baseline scores 
during the week of Session 2. However, the slope of anxiety scores between Sessions 1 to 
3 showed a steep decline, and these scores stabilized at a lower level that baseline scores 
following Session 3. Regarding depression, an isolated peak in scores was observed 
during the week of Session 2, which co-occurred with the reported worsening of an 
ongoing romantic stressor. Daily depression scores then dropped below baseline levels 
and remained at “Not at all” after the treatment midpoint (T4). P4’s frequency of positive 
emotions was lower than the range of baseline scores during the first two treatment 
sessions. By Session 3, however, scores remained at a stable level that was consistent 
with the baseline mean. After the third session of treatment, P4’s variability in daily 
depression, anxiety, Compared with weekly symptom measures, P4’s daily positive 
emotion scores during treatment were consistent with weekly PANAS PA subscale, 
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which did not differ significant from baseline levels. Her daily anxiety and depression 
scores showed more consistent improvements and lower symptom magnitude during the 
second half of treatment than did her weekly DASS-S and DASS-D subscale scores. 
Overall, her collapsed daily subscale scores indicated meaningful improvement in anxiety 
and depression scores during treatment (and specifically after Session 3), but no 
meaningful changes in positive emotions. 
P7. P7’s collapsed daily data showed a stable slope for depression symptoms and 
decreasing slopes for anxiety symptoms and positive emotions during baseline. During 
treatment, daily depression symptoms showed a horizontal slope and remained at a 
magnitude consistent with baseline. Similarly, daily positive emotion ratings during 
treatment remained at levels consistent with baseline scores and showed little change. 
Despite a small peak in daily anxiety symptoms during the week after Session 5, 
treatment anxiety ratings overall remained at a level that was consistent with baseline. 
The lack of visible changes in daily depression, anxiety, or positive emotions ratings 
during treatment stands in contrast to P7’s observed decreases in weekly DASS-S and 
DASS-D scores and increases in weekly PANAS PA scores.  
P10. P10’s collapsed daily data showed decreasing slopes for anxiety, stable 
baseline for depression symptoms, and an increasing slope for positive emotions. During 
treatment, her daily anxiety ratings showed a decreasing slope, with two visible 
elevations during the weeks of Session 2 (Introduction to LKM) and Session 6 (LKM 
toward difficult person). Overall, her daily anxiety ratings remained at a level consistent 
with baseline scores. Of note, P10’s collapsed daily anxiety ratings showed a decreasing 
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slope during treatment, whereas her weekly DASS-S and DASS-A subscale scores 
showed increasing treatment slopes. Despite this opposite pattern of symptoms change 
during treatment, the ranges of both daily and weekly anxiety scores during treatment did 
not appear visually distinct from baseline scores. P10’s daily depression ratings during 
treatment immediately stabilized at a level consistent with the baseline mean, with little 
variability. Her daily positive emotions ratings showed an overall slow rate of change 
during treatment (horizontal slope), but mean level that appeared higher than her baseline 
mean. Because her positive emotions spontaneously improved during baseline, it is 
impossible to determine whether further improvements during treatment were due to the 
study intervention or the effect of time. Finally, P10’s collapsed daily and weekly DASS-
D subscale scores both revealed low base levels of depression symptoms and no 
significant visual changes in depression during treatment compared with baseline. 
Overall, P10’s daily symptom ratings revealed no reliable changes in anxiety, depression, 
or positive emotions attributable to the study intervention. 
P1. P1’s collapsed daily data showed stable baselines for depression and positive 
emotions, and an increasing baseline for anxiety symptoms. During treatment, her daily 
anxiety ratings remained consistent with baseline scores except for elevated ratings after 
Session 5, which corresponded in time with reported academic stressors. Following 
Session 1, depression ratings reduced to a slightly lower level than baseline scores and 
remained stable at that level throughout treatment. In contrast, daily positive emotions 
ratings during treatment did not differ in slope or magnitude from baseline scores. P1’s 
collapsed daily ratings of depression and positive emotion symptoms were consistent 
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with her scores on weekly measures of similar constructs (DASS-D and PANAS PA, 
respectively). In contrast, her weekly scores on the primary measure of anxiety (DASS-S) 
showed an immediate, large reduction in anxiety symptoms following the introduction of 
the study intervention, unlike her daily ratings. Ultimately, this reduction in weekly 
symptoms of anxiety was unstable, and the majority of both daily and weekly anxiety 
scores were consistent with baseline anxiety scores. Overall, P1’s daily symptom ratings 
revealed small reductions in daily depression symptoms following the introduction of the 
study intervention, but no reliable changes in daily anxiety or positive emotions. 
Summary of Collapsed Daily Data Results. Across all study completers, visual 
analysis of collapsed daily data revealed distinct improvements in depression symptoms 
for five participants (P1, P2, P4, P5, P11), no improvements in depression symptoms for 
three participants (P7, P10, P12), and worsening of depression symptoms for P8. 
Notably, all five participants who reported improvement in their daily experience of 
depression symptoms during treatment had either a principal or additional depressive 
disorder diagnoses at baseline; the other participants did not report significant depression 
disorder symptoms at baseline. Regarding collapsed daily anxiety ratings, only two 
participants (P4 and P11) demonstrated visual improvements during treatment. The other 
seven participants demonstrated no changes in daily anxiety during treatment. Finally, 
two participants demonstrated increases in frequency of daily positive emotions during 
treatment (P5 and P11), P4 showed a decrease in mean level of positive emotions, and the 
rest of the participants showed no changes in positive emotions during treatment.  
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 Next, patterns of symptom change in the collapsed daily data were visually 
analyzed to determine whether changes in positive emotions preceded changes in 
principal disorder symptoms. Of the three participants with principal depressive disorders 
who showed improvements in depression symptoms during treatment, P2 showed no 
improvements in positive emotions, P5’s improvements in positive emotions and 
depression symptoms appeared to occur simultaneously, and P11’s depression symptoms 
improved before positive emotions improved. Only one participant with a principal 
anxiety disorder diagnosis (P4) showed improvements in daily anxiety symptoms during 
treatment. The steep decline of her anxiety symptoms during the first three sessions of 
treatment appears to precede the small increase in positive emotions by Session 3. The 
other five participants with principal anxiety disorders did not show improvements in 
either daily anxiety or daily positive emotion symptoms.  
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Discussion 
This study used a nonconcurrent multiple baseline, single-case experimental 
design to evaluate the feasibility, acceptability, and efficacy of a 7-week individual LKM 
intervention for nine outpatients with principal depression or anxiety disorders and low 
positive affect. This study showed good feasibility as demonstrated by the enrollment of 
30% (13/43) of individuals who responded to recruitment efforts and completed an initial 
phone screen. Notably, 100% of people who were found eligible for the study upon 
completion of screening procedures chose to continue in the study. One participant in the 
4-week baseline condition was lost to follow-up before beginning the study treatment and 
consequently withdrawn. Among the participants who began the study treatment, 
retention was high (90%) and consistent with studies of group LKM interventions within 
clinical samples (Hofmann et al., 2015; Johnson et al., 2011; Kearney et al., 2013). 
Participants rated the treatment as highly credible and reported levels of treatment 
satisfaction that are consistent with similar normative outpatient samples. 
 Randomization of participants to 2-, 4-, or 6-week baseline conditions and 
stabilization of baseline principal disorder symptoms before the introduction of the LKM 
intervention allowed for a controlled comparison of the effect of the study treatment 
versus time on depression and anxiety symptoms. Weekly questionnaires completed 
during 2-, 4-, and 6-week baseline periods indicated that principal depression and anxiety 
symptoms (as measured by the DASS-D and DASS-S subscales, respectively) remained 
stable or increased for all participants. Following the introduction of the study treatment 
within and across participants, visual inspection revealed that four participants (P4, P5, 
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P8, and P11) demonstrated reductions in principal outcome DASS scores. Specifically, 
two participants with principal unipolar depression disorder diagnoses (P5, P11) showed 
improvements in depression symptoms, and two participants with principal GAD 
diagnoses (P4, P8) showed improvements in anxiety symptoms. These improvements 
remained stable or increased during the 4-week follow-up period and were corroborated 
by significant PND of follow-up versus baseline scores. Although only P11 showed 
clinically reliable change in DASS symptoms via significant RCI during treatment, three 
participants (P4, P5, and P11) showed clinically reliable change in DASS symptoms 
during follow-up. In other words, changes in principal DASS outcomes observed for 
these three participants could be attributed to the study intervention rather than the effects 
of time or measurement error. Such results provide partial support for primary hypotheses 
predicting significant decreases in principal disorder symptoms during treatment and 
follow-up phases. 
Although a substantial portion of study participants showed improvements in 
principal disorder symptoms, a large minority (P1, P7, P10, and P12) demonstrated no 
visually detectable or clinically reliable changes in DASS subscales corresponding to 
principal disorder symptoms during treatment or follow-up phases. One possible 
explanation for these findings could be that LKM is more effective at treating certain 
presenting problems than others. For example, two of the study responders had principal 
depression diagnoses (P5, P11) and two had a principal GAD diagnosis (P4, P8), whereas 
none of the participants with a principal social anxiety disorder diagnosis (P1, P7, and 
P10) showed improvements in DASS-S scores during the treatment or follow-up phases. 
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A growing literature supports the efficacy of group LKM treatment for depression 
symptoms in clinical samples (Hofmann et al., 2015; Johnson et al., 2011; Kearney et al., 
2013); however, two recent treatment studies (albeit in nonclinical samples) found no 
effect of group LKM treatment on anxiety symptoms (Shahar et al., 2014; Weibel, 
McClintock, & Anderson, 2017). Participants’ collapsed daily data from this study 
further support the finding that the study intervention was more effective for reducing 
depression rather than anxiety symptoms. Perhaps LKM exerts its effects on a shared 
vulnerability factor that is strongly related to both depression and GAD, such as 
neuroticism or negative affect (Brown et al., 2007). Of all the weekly outcome variables 
tested in this study, LKM exerted its largest, negative effects on PANAS-NA and DASS-
S during the follow-up period, which would support such a hypothesis. 
Of note, two of the non-responders (P1 and P10) were the only participants who 
disclosed a significant trauma history and current PTSD symptoms during the screening 
clinical interview. On multiple occasions, both of these participants reported increased 
PTSD symptoms (e.g., memories of and perceptions related to trauma, hypervigilance, 
anger) during in-session and at-home meditation exercises, which interfered with 
attention and engagement. For example, P10, a survivor of intimate partner violence and 
a recent physical assault, expressed discomfort with closing her eyes early in treatment 
due to fears of being physically attacked. P1, a survivor of early childhood emotional and 
physical abuse, discussed how lessons learned from an abusive parent (e.g., “You’re 
worthless”) arose in her thoughts during Session 4 as she offered kindness to herself. 
Despite explicit instructions to not select trauma perpetrators as objects of meditation 
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during Session 6 (which focuses on LKM towards the difficult person), both participants 
discussed having intrusive, distressing thoughts about their perpetrators either during 
session or during homework practice that week.   
For patients with early or repeated lifetime experiences of abuse or trauma, beliefs 
that underlie the basic assumptions of LKM practice – that every living being deserves to 
be safe, happy, and healthy – may have never developed or been consistently reinforced. 
As a result, LKM teachings and associated emotions (e.g., joy, relaxation, love) may 
conflict with learned experiences (e.g., “I do not deserve to be happy,” “The world is 
unsafe,” “If I relax or show my emotions, someone will hurt me”) and produce 
skepticism or distress. From a Buddhist perspective, such cognitive and affective states 
are conceptualized as hindrances, or obstacles, to engaging in metta meditation (Salzberg, 
2002). Hence, a trauma-informed approach to LKM treatment that includes a session of 
psychoeducation on common reactions to trauma and how they may present during the 
treatment would likely have been beneficial for these participants. Also, given that the 
LKM towards the difficult person was introduced near the end of treatment, participants 
did not have much time to adjust to their reactions and develop mastery of this skill. A 
lengthier course of treatment with extended focus on the self and/or the difficult person 
may yield more successful treatment results, as shown in one recent 12-session group 
LKM treatment study for veterans with PTSD (Kearney et al., 2013).  
Despite the significant portion of non-responders on weekly measures of principal 
disorder symptoms, clinician-rated CSRs from ADIS-5 interviews conducted at baseline 
and post-treatment across all participants showed significant, large reductions in principal 
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disorder CSR across participants following treatment. Furthermore, four participants 
experienced remission of their principal psychological disorder at post-treatment, and 
three participants had no diagnosable mental disorder at post-treatment. These clinician-
rated outcomes are consistent with moderate-sized reductions in self-reported functional 
impairment due to disorder symptoms during the follow-up period, as well as large 
associated increases in quality of life.  
In addition to principal disorder symptom reduction, it was hypothesized that the 
study intervention would be associated with significant increases in positive affect. This 
study yielded mixed results regarding the effect of LKM on positive affect. For example, 
three study participants (P5, P7, and P11) showed visible improvements in positive affect 
during the intervention that remained stable during follow-up for the two participants 
with principal depression disorders (P5 and P11). On the other hand, two participants, 
both with principal GAD (P4, P12) showed significant decreases in positive affect per 
PND between baseline and treatment phases. However, only one participant (P11) 
showed clinically reliable changes (improvements) in positive affect during either the 
treatment or follow-up phases. Effect size analyses revealed no significant effect of the 
study intervention on positive affect across participants during the treatment phase, but a 
significant, small increase in positive affect during the follow-up phase. Of note, when 
P11 was excluded from the effect size analyses, this follow-up effect was non-significant. 
Therefore, it is likely that the intervention’s small effect on positive affect was driven by 
the large increases observed for P11. The relative lack of significant findings related to 
positive affect stands in contrast to increases in positive affect reported by previous LKM 
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studies in various clinical samples (Hofmann et al., 2015; Johnson et al., 2011; Kearney 
et al., 2013).  
Although psychotherapy interventions have generally targeted disorder 
symptoms, general distress, and avoidance (Garland et al., 2010), deficits in positive 
affect and maladaptive regulation of positive affect are particularly problematic in 
emotional disorders (Carl et al., 2013). One meta-analysis of positive psychology 
interventions aimed at improving positive emotions found that improvements in positive 
affect were greater for individuals with depression versus individuals without depression 
(Sin & Lyubomisky, 2009), which was also the case in this study. Given the brief nature 
of this study’s LKM intervention and the relatively intransigent nature of positive affect 
deficits among individuals with emotional disorders (Brown et al., 2007), it is possible 
that participants did not receive a sufficient enough dose of LKM to significantly 
improve positive affect.  
Another possible explanation for this weaker than expected finding is that the 
PANAS-PA was not sensitive enough to the wide range of positive emotions affected by 
LKM. For example, Zeng and colleagues (2015) noted that the PANAS PA scale, while 
commonly used in LKM research, might not adequately capture the full range of positive 
emotions targeted by LKM, such as peacefulness and social connection. To address such 
concerns within the current study, various forms of dispositional positive emotions were 
measured before and after the intervention using the DPES. Of the trait positive emotions 
that participants rated, significant improvements were only observed for Amusement. In 
other words, participants’ self-reported sense of humor and ability to feel amused 
 96 
increased after completing the intervention. Notably, changes were not observed in DPES 
subscales of Love, Compassion, or Joy, which appear at face value to be most closely 
related to the study intervention. This lack of significant findings could possibly be 
explained by a self-selection bias, such that participants with higher levels of compassion, 
love, and other positive emotional traits were more likely to participate in an LKM 
research intervention study. In such case, significant changes in such emotions would be 
harder to achieve. 
Based on Frederickson’s (1998, 2001) broaden-and-build theory and Hofmann 
and colleagues’ (2012) emotion regulation model of mood and anxiety disorders, it was 
hypothesized that changes in positive affect would precede changes in disorder symptom. 
Results from weekly outcome questionnaires did not support this hypothesis. 
Specifically, only one participant experienced clinically reliable improvement in positive 
affect during treatment, and these changes occurred simultaneously with improvements in 
disorder symptoms. Likewise, of the three participants who showed increases in positive 
affect during treatment per visual analysis and PND, none showed a functional pattern of 
changes in positive affect preceding changes in disorder symptoms. On the contrary, any 
changes in positive affect and disorder symptoms occurred simultaneously. Collapsed 
daily symptom ratings revealed mixed results regarding the temporality of changes in 
disorder symptoms (depression, anxiety) and positive emotions. For example, increases 
in positive emotions preceded decreases in disorder symptoms for one participant, 
whereas decreases in disorder symptoms preceded increases in positive emotions for two 
participants. For the other 6 participants, there was either no evidence of either 
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improvement in principal disorder symptoms or positive affect. Further studies are 
needed to better understand the impact of individual LKM treatment on positive emotions 
in individuals with depression and anxiety disorders.  
 As expected, the majority of participants showed visual improvements in negative 
affect during treatment, which either remained stable or further improved during the 
follow-up phase. In addition, all but one participant showed visibly lower levels of 
negative affect during the follow-up phase compared to baseline levels. These results are 
logical when considering the measurement properties of the PANAS NA scale. For 
example, higher scores on this subscale reflect the presence of general distress and 
unpleasant emotional states, whereas lower scores reflect the absence of such distress and 
involve emotional states of calmness and serenity (Watson et al., 1988). One of the skills 
that LKM seeks to develop is the ability to peacefully observe both pleasant and 
unpleasant reactions that arise in the mind and body without becoming overly attached to 
them. Within this small treatment sample, it can be argued that large reductions in 
negative affect between baseline and follow-up phases across participants reflect the 
development of equanimity, or composure in the face of changing inner experiences and 
outer circumstances.  
 LKM demonstrated a small effect on weekly ratings of state anger during the 
treatment phase and a moderate effect by the follow-up phase. Perhaps most interesting 
about these findings is their specificity to patients presenting with principal depression 
diagnoses. Specifically, P5 and P11 showed clinically reliable changes in state anger 
during treatment, and all three participants in the depression condition (P2, P5, and P11) 
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showed clinically reliable changes in state anger during follow-up. It would be interesting 
for future studies to examine whether improvements in anger were related to self- or 
other-focused anger, since depression likely involves more inward-focused anger and 
self-criticism than anxiety disorders, which are by nature focused on external threats. 
Although the intervention was not associated with significant reductions in trait anger, 
participants’ scores overall trended towards post-treatment decreases in anger. Larger 
sample sizes would help to detect any meaningful effects of LKM on trait anger. 
The study intervention exerted significant moderate-to-strong, positive treatment 
effects on certain facets of mindfulness (Nonjudging of and Nonreactivity to Inner 
Experiences). By the follow-up phase, LKM continued to show moderate effects on those 
facets of mindfulness (with two participants showing reliable changes in each facet). In 
addition, moderate increases in the Act with Awareness facet was observed across 
participants; however, this effect was likely driven by P11’s clinically reliable 
improvement. The strongest effects observed during the treatment phase occurred on the 
FFMQ Nonreactivity subscale. These effects appeared largely driven by reliable changes 
for two participants with principal depression diagnoses (P5 and P11). Previous research 
has demonstrated that nonreactive observation of inner thoughts and emotions indirectly 
moderates the relationship between observational awareness and depression-related 
cognitive symptoms (e.g., worry, rumination) through cognitive reappraisal (McEvoy et 
al., 2010).  
Regarding changes in affective styles, participants overall showed moderate-sized 
improvements in their use of the Tolerating affective style, which encourages individuals 
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to meet difficult emotional experiences (positive or negative) with acceptance rather than 
attempts to avoid (Hofmann & Kashdan, 2010). This result was expected, as LKM 
advises individuals to embrace difficult emotional reactions (i.e., “May I hold this anger 
with kindness”) rather than attempt to eliminate or suppress them. 
Strengths 
This study has several strengths, first and foremost being the use of a multiple 
baseline design that controlled for various threats to internal validity, such as the natural 
effects of time, self-monitoring, regression to the mean, and measurement error. The 
single-case nature of the study allowed each participant to serve as their own control 
while the study intervention was introduced after a period of initial symptom stability, 
then withdrawn. The use of two replications for each baseline condition allowed for 
between-subjects comparisons to further understand the impact of treatment versus the 
passage of time. In addition, the individual nature of the LKM treatment allowed 
flexibility to adapt the structured intervention components to best fit each individual’s 
contextual circumstances (e.g., baseline symptoms, trauma history, affective regulation 
styles, tendency towards boredom, distress, or anger during meditation, etc.). In addition, 
the study intervention is brief, which makes it easier to offer to more individuals. This 
was also the first known evaluation of an individual LKM intervention in a clinical 
sample of outpatients with depression and / or anxiety disorders and low positive affect. 
Within and across participants, the presence of stable (or increasing) baselines and 
relatively immediate improvements in depression and anxiety symptoms after the 
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introduction of the study treatment for a significant portion of participants offers 
promising preliminary evidence for this novel intervention.  
Limitations 
Although multiple baseline, single-case experimental designs protect against 
numerous threats to internal validity, this methodology comes with limitations to external 
validity. For example, the small sample size limits generalizability to larger and broader 
outpatient populations. In addition, the small sample size precluded any evaluation of 
mechanisms of change during treatment. Studying LKM with larger samples would 
provide adequate power for mediation analyses that could detect true functional 
relationships between outcome variables. Due to the study’s nonconcurrent baselines, 
notable life stressors (e.g., academic exams, physical illness, relationship stressors) were 
recorded during treatment for each participant to better understand ideographic variables 
related to treatment outcomes. Future studies using nonconcurrent multiple baseline 
designs would benefit from using valid and reliable measures of life stress to 
systematically track the impact of external stressors on disorder symptoms. 
Given that outpatients typically present with a variety of comorbid anxiety, 
depression, and related disorders, the use of three groups of participants with different 
principal diagnoses and diverse secondary diagnoses boosted this study’s external 
validity. On the other hand, future studies may elucidate a more nuanced understanding 
of LKM’s disorder- and construct-specific effects by focusing on a narrower range of 
presenting concerns (i.e., only certain depression or anxiety disorders).  
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This was a preliminary evaluation of the effects of individual LKM as a viable 
intervention for a small group of individuals with anxiety or depression disorders and low 
levels of positive affect. As such, an open-label trial of the intervention was appropriate. 
However, the absence of a control condition makes it impossible to understand the effect 
of nonspecific therapeutic factors (e.g., therapeutic alliance, positive regard, structure) or 
how the intervention fares compared to other evidenced-based interventions for 
depression and anxiety (e.g., cognitive-behavioral therapies, exposure therapies, etc.). It 
would be particularly interesting to compare LKM with mindfulness-based therapies that 
are not specifically emotion-focused, such as Acceptance and Commitment Therapy or 
Mindfulness-Based Cognitive Therapy (Segal, Williams, & Teasdale, 2002).   
 Across all study variables, the most consistent improvements across primary and 
secondary outcomes were observed among participants with principal depressive 
disorders (P5, P11). Further research is needed to better understand how individuals with 
depressive disorders respond to LKM interventions, and specifically which factors may 
be most closely related to depression symptom change during the intervention. Given that 
the intervention showed the strongest effects on measures of general negative affect and 
tension (e.g., DASS-S subscale, PANAS NA subscale), future studies may do well to 
target transdiagnostic samples with high levels of negative affect and tension. In addition, 
the inclusion of weekly measures of emotional regulation strategies may help elucidate 
possible mechanisms behind changes in negative affect and general tension. For example, 
changes in emotion regulation styles, and particularly the adoption of more flexible 
emotion regulation styles, may precede changes in negative affect or neuroticism. 
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 Little is known about optimal format or dosing of LKM interventions. This study 
employed an individual treatment format and a relatively brief dose (7 weeks). Only one 
participant specifically recommended a longer course of treatment in her feedback 
survey. However, based on anecdotal observations by the study clinician, many of the 
participants showed less overt frustration and significant improvement in their ability to 
sit still during meditation exercises by Session 4. During the second half of treatment, 
LKM towards the self and LKM towards the difficult person were both introduced. These 
objects of meditation proved challenging for many of the study participants (especially 
those with significant trauma histories), and may warrant additional sessions or perhaps 
separate interventions.  
Conclusion 
In conclusion, this study provided a robust preliminary evaluation of a novel and 
brief, individual LKM treatment for outpatients with clinical depression or anxiety and 
low levels of positive affect. Treatment results revealed that the strongest intervention 
effects occurred for negative affect, a specific facet of mindfulness (Nonreactivity to 
Inner Experiences), DASS-D symptoms, DASS-S symptoms, and quality of life. In 
addition, the most consistent changes in primary and secondary outcomes occurred in two 
participants with principal depression disorders. Given that effects were generally 
strongest during the follow-up phase, it is possible that a longer course of LKM is 
required to produce meaningful symptom change during treatment. In addition, the 
intervention would likely benefit from the integration of disorder-specific 
psychoeducation, specifically for those with significant trauma histories. Future studies 
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would benefit from using larger sample sizes and focusing on individuals with unipolar 
depression disorders and high levels of neuroticism or related temperamental variables in 
order to elucidate possible mechanisms for these treatment effects.   
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Appendix A  
Participant Feedback Form 
Your feedback on this study’s treatment is important to us. Please answer the following 
questions as honestly as possible: 
 
1. Overall, how acceptable was the intervention to you? In other words, did you think that 
the treatment approach and activities were reasonable and made sense? (Circle answer) 
 
Not at all 
acceptable 
Slightly 
acceptable 
Moderately 
acceptable 
Very 
acceptable 
Extremely 
acceptable 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
2. Overall, how satisfied were you with the intervention? (Circle answer) 
 
Not at all 
acceptable 
Slightly 
acceptable 
Moderately 
acceptable 
Very 
acceptable 
Extremely 
acceptable 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
3. In your own words, please tell us what you thought of the intervention overall: 
 
 
 
4. Which elements of the treatment did you find to be most helpful? 
 
 
 
5. Which elements of the treatment did you find to be least helpful? 
 
 
 
6. What changes would you recommend? 
 
 
 
7. What are the most helpful things you learned from this treatment? 
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Appendix B 
 
Study Intervention Protocol Detailed Outline 
 
Session 1 
 
I. Intro (5 mins) 
a. Please arrive 15 minutes early to fill out treatment questionnaires. 
b. If you are going to be late or can’t come, please call or email me as soon 
as you know. 
c. Please do practice assignments as directed. 
d. I will be doing these practices with you in session and you’ll have taped 
materials to guide your practice at home. 
II. Introduction (5 mins) 
a. What brought you here 
b. A joy, a passion, something you love, a hobby 
c. What are you expecting from this experience? 
d. What do you know about meditation? Have you practiced it before? 
III. Mindfulness Talk (10 mins) 
a. Qualities of mindfulness (handout). 
b. Mindfulness is the foundation of LKM that you will practice in future 
sessions. 
IV. Raisin Exercise (10 mins) 
a. Exercise – Use Kabat-Zinn script 
b. Discussion (how was for you? what did you experience?...) 
c. Key Points to note:  
i. 1. The difference between mindful awareness and autopilot 
ii. 2. How paying full attention can reveal things we had not noticed 
or had forgotten 
iii. 3. How easily the mind wanders - and that it is important to accept 
this and not become frustrated.  
 
Now we are going to try a different exercise working with the same ideas. Now 
focus your attention in the same way you did with the raisin, on the physical 
sensation of your breath.  
 
V. Mindful Body Scan Practice (20 mins) 
a. Exercise – Use body scan meditation script 
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b. Discussion - How did that go for you? What did you experience? Feel free 
to share any thoughts that came to mind during practice or that are coming 
to mind now. 
c. Key Points to note: 
i. 1. Sensations we constantly experience like the breath, can feel 
very different when we become fully aware of them. 
ii. 2. The mind will always wander, it is not about having absolute 
control. We must accept this and continue to practice. 
iii. 3. One may not enjoy this process or feel they are getting much out 
of it at first. Try not to have rigid expectations of yourself or of the 
meditation. 
VI. Applying Mindfulness (10 mins) 
a. Worksheet examining situations and your emotional reaction. 
VII. Practice Assignment (5 mins) 
a. Practice mindfulness of the breath for 30 minutes each day using the 
recording. 
b. Choose one activity during your week to perform mindfully 
c. Fill out the daily practice diary  
VIII. Closing Statement (5 mins) 
a. “Before we leave I would like to read a poem that speaks to some of the 
ideas of our practice. The poems here are used to try to help explain 
difficult concepts. There is no need to deeply analyze or understand the 
poem, it is simply a brief message to take home.” 
 
 
Session 2 
 
I. Opening Meditation (5-10 mins) 
a. Exercise – mindfulness of breath with an initial focus on thoughts and 
emotions (Breathing Space exercise) 
b. Discussion 
i. Key Points to Note: 
ii. Thoughts and emotions are natural and temporary occurrences. 
They do not define us. When observed with a non-judgmental eye 
they can be seen simply as mental events with no real positive or 
negative implication. 
iii. It is important to accept thoughts and sensations as they are and 
not try to bend them.  
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II. Discussion of past week’s homework (10 mins) 
III. Intro to LKM (20 mins) 
a. Intro to LKM Handout  
i. personal reactions to LKM 
ii. Recall a time when you experienced kindness, friendliness or 
goodheartedness. What were the thoughts, emotions and bodily 
sensations?  
b. Brief definition of metta & rationale for treatment 
Definition of metta:  
Metta can be translated as “unconditional love and kindness.” We can also think of metta 
as a practice of becoming a good friend to ourselves, other people, and all living beings. 
 
What are some qualities of a good friend? 
• someone who is there in times of happiness and also stands by us in times of 
adversity or unhappiness 
• they take no pleasure in our misfortune 
• they help us and protect us when we are unable to take care of ourselves 
• they are a refuge when we are afraid 
 
Rationale: 
The practice of metta meditation is intended to increase feelings of warmth and caring for 
the self and others. Through this practice, people can deliberately strengthen qualities like 
kindness that make their lives more enjoyable and satisfying. With practice, you can learn 
to meet difficult experiences, like anxiety and depression, with this unconditional 
goodwill and kindness.  
 
c. LKM Phrases (handout) 
i. “In practicing loving-kindness meditation we will be gently 
repeating these phrases; directing the compassion and acceptance 
they embody towards different groups of people and towards 
ourselves. When doing this, try not to slip into just repeating them 
on auto-pilot mode. Instead, try to utter the phrases mindfully each 
time, bringing your full awareness to the phrases, their meaning, 
and the feelings they bring up. You can also experiment with your 
phrases as you go, and change them to best suit your own 
practice” 
IV. LKM practice (15 minutes) 
a. One way to begin the process of discovering and strengthening qualities of 
friendliness and kindness is to think of someone who has helped you. 
Bring to mind a person who has shown you kindness and understanding. It 
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could be anyone: a friend, a teacher, a military brother or sister, a doctor, 
even a stranger. In this meditation practice, this person is called a 
benefactor. See the goodness in this person. Be mindful of your own 
thoughts and feelings when you bring to mind this person.  
1. What did this person do that was helpful?  
2. How would you describe this person’s positive qualities?  
3. How do you feel when you bring this person to mind?  
4. Imagine wanting this person to be happy. What is this like for you? How does 
this feel? Is it easy? Hard?  
5. How does it feel in your body when you think of wishing this person happiness?  
b. LKM Exercise: Benefactor  
c. Discussion – What was LKM like for you? 
V. Practice Assignment (5 mins) 
a. Mindfulness + LKM of Benefactor for 10 minutes each day (or more) 
b. Notice a time when you experienced kindness, friendliness or 
goodheartedness. What were the thoughts, emotions and bodily 
sensations?  
VI. Closing Meditation (10 mins) 
a. Poem 
b. Mindfulness of breath closing meditation 
 
 
Session 3 
 
I. Opening Meditation (breathing space exercise) (5 mins) 
a. Discussion 
II. Discussion of last week’s practice assignment (10 mins) 
a. Noticing reactions to kindness (thoughts, emotions, bodily sensations) 
b. Reactions to practicing LKM to benefactor – What were the thoughts, 
emotions, and bodily sensations that you experienced? 
III. Hindrance to LKM handout and discussion. 
IV. Intro to LKM to beloved one (10 mins) 
a. Personal reflections about kindness to a beloved friend 
b. Intro to altered LKM phrases 
V. LKM exercise: Benefactor + focus on Beloved one (20 mins) 
a. LKM for a benefactor + beloved one (can also recommend pet, animal, 
someone who did something kind for them) – 15 mins 
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b. Discussion (what was this LKM exercise like for you? – 5 mins 
VI. Practice Assignment (5 mins) 
a. Daily LKM practice for benefactor and beloved one  
VII. Closing Meditation (10 mins) 
a. poem 
b. breathing meditation 
 
 
Session 4 
 
I. Opening Meditation (breathing space exercise) (5 mins) 
a. Discussion 
II. Discussion of last week’s practice assignment (10 mins) 
a. Reactions to practicing LKM to benefactor + beloved one – What were the 
thoughts, emotions, and bodily sensations that you experienced? 
b. Did you notice any barriers to LKM arising? (attachment/desire) 
III. Intro to LKM to self (15 mins) 
a. Kindness Towards Oneself handout/reactions 
i. personal reflections – what has it been like to wish yourself 
happiness/goodwill? 
IV. LKM exercise: Benefactor + Beloved one + focus on Self (25 mins) 
a. LKM for a benefactor + beloved one + self – 20 mins 
b. Discussion - what was this LKM practice like for you? – 5 mins 
V. Practice Assignment (5 mins) 
a. Daily LKM towards self practice  
b. Notice instances of distress, anger, sadness, disappointment and meet the 
difficult emotions with brief loving-kindness toward the self. 
VI. Closing Meditation (10 mins) 
a. poem 
b. breathing meditation 
 
 
Session 5 
 
I. Opening Meditation (breathing space exercise) (5 mins) 
a. Discussion 
II. Discussion of last week’s practice assignment (10 mins) 
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a. Reactions to practicing LKM to benefactor + beloved one + self– What 
were the thoughts, emotions, and bodily sensations that you experienced? 
III. Intro to LKM to neutral person (10 mins) 
a. Kindness Towards Neutral Person Handout – reactions? 
IV. LKM exercise: Benefactor + Beloved one + Self + focus on Neutral Person 
(30 mins) 
a. LKM for a benefactor + beloved one + self + neutral person – 25 mins 
b. Discussion - what was this LKM practice like for you? – 5 mins 
V. Practice Assignment (5 mins) 
a. Daily LKM towards neutral person practice  
b. Notice any acts of Loving-kindness you receive from neutral persons that 
occur in your daily life. This might be a person who you don’t know 
helping you out in some way. 
VI. Closing Meditation (10 mins) 
a. poem 
b. breathing meditation 
 
Session 6 
 
I. Opening Meditation (breathing space exercise) (5 mins) 
a. Discussion 
II. Discussion of last week’s practice assignment (10 mins) 
a. Reactions to practicing LKM to benefactor + beloved one + self + neutral 
person – What were the thoughts, emotions, and bodily sensations that you 
experienced? 
III. Intro to LKM to difficult person (10 mins) 
a. Kindness Towards Difficult Person Handout – reactions? 
b. Personal reflections  
c. Teaching points  
o Begin with a person with whom the difficulty is relatively mild.  
o Someone mildly irritating or annoying  
o (not a person who has hurt you deeply in your life)  
o Practicing LKM does not excuse their actions: “You should never 
exclude someone from your heart, but you can exclude them from 
your life”  
o “We are not asking you to like them, only to love them”, i.e. this is 
not a sentimental love. Rather it is recognition that they too are 
human beings, trying to be happy.  
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IV. LKM exercise: Benefactor + Beloved one + Self + Neutral Person + focus on 
Difficult Person  (35 mins) 
a. LKM for a benefactor + beloved one + self + neutral person – 25 mins 
b. Discussion - what was this LKM practice like for you? – 5 mins 
V. Practice Assignment (5 mins) 
a. Daily LKM towards difficult person practice 
b. Experiment with the informal practice of loving-kindness. Try the 
situations identified above or come up with your own situations.  
c.  Notice if there is any positive intention behind the actions of difficult 
persons that you encounter in your daily life. Even though you find their 
actions difficult, annoying or irritating, are their actions a misguided 
attempt to find happiness for themselves?  
d. Reaction to relevant poem 
VI. Closing Meditation (5 mins) 
a. breathing meditation 
 
Session 7 
 
VII. Opening Meditation (breathing space exercise) (5 mins) 
a. Discussion 
VIII. Discussion of last week’s practice assignment (10 mins) 
a. Reactions to practicing LKM to benefactor + beloved one + self + neutral 
person + difficult person – What were the thoughts, emotions, and bodily 
sensations that you experienced? 
IX. Intro to LKM to Groups + All Living Beings (10 mins) 
a. Groups Teaching Points:  
i. LKM for groups helps us to see the resistances and barriers we 
have to open-heartedness.  
ii. Practicing LKM for groups helps us to see our concepts of 
division.  
b. Suggested groups: men and women, people I know and people I don’t 
know, your racial/ethinic group vs a different racial/ethnic group 
X. Intro to expanding groups to all living beings 
a. “Reflect on your desire to be happy. Then reflect on the fact that all beings 
want to be happy.” “Just as I want to be happy, all [children, refugees, 
republicans, people, animals, living beings] want to be happy.” Use this as 
a transition to practicing loving-kindness for all beings.  
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b. When practicing loving-kindness for all beings, make sure to include 
yourself.  
c. Working with descriptions of beings is one way of feeling the vastness of 
loving- kindness – all in this room, in this hospital, in this neighborhood, 
city, state, nation…etc.  
d. Or, categories: all beings, all living beings, all creatures, all individuals, all 
those in existence  
XI. LKM exercise: Benefactor or Beloved one + Groups + All Living Beings (20 
mins) 
a. LKM for a benefactor + groups + all living beings – 20 mins 
XII. Discussion (20 mins) 
a. Discussion - what was this LKM practice like for you? – 5 mins 
b. Discussion of whole study 
i. What was difficult/what did you benefit from? 
ii. Were you surprised by any part of this program? What about your 
reactions to learning LKM? 
iii. How has the practice of meditation impacted you? 
iv. How did you overcome obstacles to practicing? 
c. How to continue the practice  
• Personal practice (formal/informal) 
• Community resources  
• MBSR if not already taken  
XIII. Final Closing Meditation (5 mins) 
a.  “Whenever a thought of giving enters your mind, do it. Whether it is a gift 
of money, time, helping care, or offering a possession, if you even think of 
a generous act, follow it. Sometimes we worry that we will regret our 
generous acts, we second-guess ourselves, and a bit of doubt comes in. 
Don’t believe the doubts. Instead, look for any spontaneous thoughts of 
generosity and follow them. You will find that they inevitably make you 
happy. Try it.”  
- Jack Kornfield  
b. Final breathing meditation 
 
 
 
 
 
 113 
Appendix C 
Treatment Adherence Rating Forms 
 
Loving-kindness Meditation for Mood and Anxiety Disorders 
Therapist Adherence Rating Scale 
Session 1 (75 minutes) 
Subject ID: _________    Rater Initials: _________  
Session Date: _________    Date Rated: _________  
I. Introduction to LKM treatment 
Did the therapist do the following (circle yes or no to indicate presence / absence):  
Yes      No  (1) Explain the rationale for treatment  
Yes      No  (2) Describe the treatment procedures 
Yes      No  (3) Discuss patient’s expectations and reasons for change 
II. Introduction to Mindfulness  
Did the therapist do the following (indicate only presence or absence):  
Yes      No  (4) Introduce definition of mindfulness & qualities of mindfulness 
Yes      No  (5) Complete the Raisin Exercise, in which the participant notices 
thoughts, feelings, and behavioral urges related to eating a raisin 
Yes      No  (6) Complete the Mindful Breathing Exercise, in which the participant 
attends to his/her breath as it occurs in the present moment 
Yes      No  (7) Discuss strategies for applying mindfulness to observe everyday 
situations and emotional reactions  
Homework Assignment:  
Did the therapist do the following (indicate only presence or absence):  
 114 
Yes      No  (8) Assign daily meditation practice and discuss Meditation Practice Form 
for participant to track practice. 
Yes      No  (9) Assign reflection practice: Choose two activities during the week to 
perform mindfully and write a brief reflection on the exercise. 
Session Duration:  
Yes      No  (10) Session duration is between 60-90 minutes?  
Disallowed interventions:  
Yes     No  (11) Therapist did NOT implement interventions that are not included in 
this manual or model of treatment (e.g., formal cognitive restructuring, 
behavioral activation)? 
If “No,” describe:  
________________________________________________________________ 
Adherence Summary Score:  
Total “Yes” _____ / (Total “Yes” _____ + Total “No” _____) = Total Adherence Score 
_____ 
Overall Therapist Rating:  
(8) Please provide an overall rating for therapist during this treatment session, taking into 
consideration how effectively the therapist presented key treatment elements and met the 
primary goals of the session.  
0 1 2 3 4 5 
Poor Marginal Fair Adequate Good Excellent 
 
Overall Session Rating:  
(8) Please provide an overall rating for this treatment session, taking into consideration 
the therapist’s ability to maintain rapport, engage in collaborative treatment dialogue, 
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manage the session, and effectively deliver treatment concepts.  
0 1 2 3 4 5 
Poor Marginal Fair Adequate Good Excellent 
 
(9) Pass/Fail: 
___Pass  ___ Fail  
Note: “Pass” = (1) The session duration is between 60-90 minutes in length AND (2) No 
significant disallowed interventions were administered AND (3a) total adherence score is 
80% or greater OR (3b) the overall session was rated as being at least “Adequate.”  
 
Loving-kindness Meditation for Mood and Anxiety Disorders 
Therapist Adherence Rating Scale 
Session 2 (75 minutes) 
Subject ID: _________    Rater Initials: _________  
Session Date: _________    Date Rated: _________  
I. Opening the Session 
Did the therapist do the following (circle yes or no to indicate presence / absence):  
Yes      No  (1) Complete at least 5 minutes of mindfulness meditation in the first half 
of session 
Yes      No  (2) Review homework assigned and assess for any difficulty with 
completing the homework forms 
II. Introduction to Loving-Kindness (metta) Meditation 
Did the therapist do the following (indicate only presence or absence):  
Yes      No  (3) Complete Introduction to LKM worksheet 
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Yes      No  (4) Introduce definition of loving-kindness (metta) 
Yes      No  (5) Present and discuss LKM Phrases handout 
III. LKM Practice 
Did the therapist do the following (indicate only presence or absence):  
Yes      No  (6) Introduce concept of a benefactor and help participant select 
benefactor 
Yes      No  (7) Complete LKM towards the benefactor 
Yes      No  (8) Discuss participant’s reaction to this exercise (e.g., emotional 
reactions, thoughts, how it felt in the body, ease/difficulty of the exercise)  
IV. Closing the Session 
Did the therapist do the following (indicate only presence or absence):  
Yes      No  (9) Assign daily meditation exercise to be tracked with Meditation 
Practice Form  
Yes      No  (10) Assign Reflection Practice: Participant should notice 3 times when he 
or she experienced kindness, friendliness, or goodheartedness and describe 
what thoughts, emotions, and bodily sensations occurred. 
Yes      No  (11) Complete at least 5 minutes of mindfulness of breath meditation to 
end session 
Session Duration:  
Yes      No  (12) Session duration is between 60-90 minutes?  
Disallowed interventions:  
Yes     No  (13) Therapist did NOT implement interventions that are not included in 
this manual or model of treatment (e.g., formal cognitive restructuring, 
behavioral activation)? 
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If “No,” describe:  
________________________________________________________________ 
 
Adherence Summary Score:  
Total “Yes” _____ / (Total “Yes” _____ + Total “No” _____) = Total Adherence Score 
_____ 
Overall Therapist Rating:  
(8) Please provide an overall rating for therapist during this treatment session, taking into 
consideration how effectively the therapist presented key treatment elements and met the 
primary goals of the session.  
0 1 2 3 4 5 
Poor Marginal Fair Adequate Good Excellent 
 
Overall Session Rating:  
(8) Please provide an overall rating for this treatment session, taking into consideration 
the therapist’s ability to maintain rapport, engage in collaborative treatment dialogue, 
manage the session, and effectively deliver treatment concepts.  
0 1 2 3 4 5 
Poor Marginal Fair Adequate Good Excellent 
 
(9) Pass/Fail: 
___Pass  ___ Fail  
Note: “Pass” = (1) The session duration is between 60-90 minutes in length AND (2) No 
significant disallowed interventions were administered AND (3a) total adherence score is 
80% or greater OR (3b) the overall session was rated as being at least “Adequate.”  
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Loving-kindness Meditation for Mood and Anxiety Disorders 
Therapist Adherence Rating Scale 
Session 3 (75 minutes) 
Subject ID: _________    Rater Initials: _________  
Session Date: _________    Date Rated: _________  
I. Opening the Session 
Did the therapist do the following (circle yes or no to indicate presence / absence):  
Yes      No  (1) Complete at least 5 minutes of breathing meditation in the first half of 
session 
Yes      No  (2) Review homework assigned and assess for any difficulty with 
completing the homework forms 
II. Hindrances to LKM 
Did the therapist do the following (indicate only presence or absence):  
Yes      No  (3) Discuss anger, desire, and attachment as hindrances to LKM practice 
Yes      No  (4) Help the participant reflect on experiences of anger, desire, and 
attachment (e.g., what types of thoughts and sensations these emotions 
produce) and how they weaken intentions of unconditional kindness  
III. LKM to a Beloved One Practice 
Did the therapist do the following (indicate only presence or absence):  
Yes      No  (5) Introduce concept of a beloved one and help participant select beloved 
one 
Yes      No  (6) Help participant generate LKM phrases to use in directing metta 
towards beloved one 
Yes      No  (7) Complete LKM towards: the benefactor, then beloved one 
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Yes      No  (8) Discuss participant’s reaction to this exercise (e.g., emotional 
reactions, thoughts, how it felt in the body, ease/difficulty of the exercise)  
 
V. Closing the Session 
Did the therapist do the following (indicate only presence or absence):  
Yes      No  (9) Assign daily LKM exercise (toward benefactor plus beloved one) to be 
tracked with Meditation Practice Form  
Yes      No  (10) Assign daily Reflection practice: Participant should notice a time 
when he or she had a negative emotion (e.g., anger, desire, attachment) 
towards others during daily activities and instead chose to cultivate an 
attitude of unconditional kindness and goodwill.  
Yes      No  (11) Complete at least 5 minutes of mindfulness of breath meditation to 
end session 
Session Duration:  
Yes      No  (12) Session duration is between 60-90 minutes?  
Disallowed interventions:  
Yes     No  (13) Therapist did NOT implement interventions that are not included in 
this manual or model of treatment (e.g., formal cognitive restructuring, 
behavioral activation)? 
If “No,” describe:  
________________________________________________________________ 
Adherence Summary Score:  
Total “Yes” _____ / (Total “Yes” _____ + Total “No” _____) = Total Adherence Score 
_____ 
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Overall Therapist Rating:  
(8) Please provide an overall rating for therapist during this treatment session, taking into 
consideration how effectively the therapist presented key treatment elements and met the 
primary goals of the session.  
0 1 2 3 4 5 
Poor Marginal Fair Adequate Good Excellent 
 
Overall Session Rating:  
(8) Please provide an overall rating for this treatment session, taking into consideration 
the therapist’s ability to maintain rapport, engage in collaborative treatment dialogue, 
manage the session, and effectively deliver treatment concepts.  
0 1 2 3 4 5 
Poor Marginal Fair Adequate Good Excellent 
 
(9) Pass/Fail: 
___Pass  ___ Fail  
Note: “Pass” = (1) The session duration is between 60-90 minutes in length AND (2) No 
significant disallowed interventions were administered AND (3a) total adherence score is 
80% or greater OR (3b) the overall session was rated as being at least “Adequate.”  
 
Loving-kindness Meditation for Mood and Anxiety Disorders 
Therapist Adherence Rating Scale 
Session 4 (75 minutes) 
Subject ID: _________    Rater Initials: _________  
Session Date: _________    Date Rated: _________  
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I. Opening the Session 
Did the therapist do the following (circle yes or no to indicate presence / absence):  
Yes      No  (1) Complete at least 5 minutes of breathing meditation in the first half of 
session 
Yes      No  (2) Review homework assigned and assess for any difficulty with 
completing the homework forms 
II. LKM to the Self Practice 
Did the therapist do the following (indicate only presence or absence):  
Yes      No  (3) Complete reflection worksheet on experience of wishing oneself 
happiness and goodwill 
Yes      No  (4) Help participant generate LKM phrases to use in directing metta 
towards the self 
Yes      No  (5) Complete LKM towards: the benefactor, then beloved one, then the 
self (order of meditation targets is flexible, but with the goal of extended 
meditation on a the self) 
Yes      No  (6) Discuss participant’s reaction to this exercise (e.g., emotional 
reactions, thoughts, how it felt in the body, ease/difficulty of the exercise)  
V. Closing the Session 
Did the therapist do the following (indicate only presence or absence):  
Yes      No  (7) Assign daily LKM exercise (toward benefactor plus beloved one plus 
self) to be tracked with Meditation Practice Form  
Yes      No  (8) Assign daily Reflection practice: Participant should notice instances of 
distress, anger, sadness, and disappointment with the self and chose to 
meet these difficult emotions with loving-kindness towards the self.  
Yes      No  (9) Complete at least 5 minutes of mindfulness of breath meditation to end 
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session 
Session Duration:  
Yes      No  (10) Session duration is between 60-90 minutes?  
Disallowed interventions:  
Yes     No  (11) Therapist did NOT implement interventions that are not included in 
this manual or model of treatment (e.g., formal cognitive restructuring, 
behavioral activation)? 
If “No,” describe:  
________________________________________________________________ 
Adherence Summary Score:  
Total “Yes” _____ / (Total “Yes” _____ + Total “No” _____) = Total Adherence Score 
_____ 
Overall Therapist Rating:  
(8) Please provide an overall rating for therapist during this treatment session, taking into 
consideration how effectively the therapist presented key treatment elements and met the 
primary goals of the session.  
0 1 2 3 4 5 
Poor Marginal Fair Adequate Good Excellent 
 
Overall Session Rating:  
(8) Please provide an overall rating for this treatment session, taking into consideration 
the therapist’s ability to maintain rapport, engage in collaborative treatment dialogue, 
manage the session, and effectively deliver treatment concepts.  
0 1 2 3 4 5 
Poor Marginal Fair Adequate Good Excellent 
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(9) Pass/Fail: 
___Pass  ___ Fail  
Note: “Pass” = (1) The session duration is between 60-90 minutes in length AND (2) No 
significant disallowed interventions were administered AND (3a) total adherence score is 
80% or greater OR (3b) the overall session was rated as being at least “Adequate.”  
 
 
Loving-kindness Meditation for Mood and Anxiety Disorders 
Therapist Adherence Rating Scale 
Session 5 (75 minutes) 
Subject ID: _________    Rater Initials: _________  
Session Date: _________    Date Rated: _________  
I. Opening the Session 
Did the therapist do the following (circle yes or no to indicate presence / absence):  
Yes      No  (1) Complete at least 5 minutes of breathing meditation in the first half of 
session 
Yes      No  (2) Review homework assigned and assess for any difficulty with 
completing the homework forms 
II. LKM to Neutral Person Practice 
Did the therapist do the following (indicate only presence or absence):  
Yes      No  (3) Discuss reactions to topic of directing kindness towards neutral people 
Yes      No  (4) Help participant choose/visualize a neutral person for LKM practice 
Yes      No  (5) Complete LKM towards: the benefactor, then beloved one, the self, 
then a neutral person (order of meditation targets is flexible, but with the 
goal of extended meditation on a neutral person) 
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Yes      No  (6) Discuss participant’s reaction to this exercise (e.g., emotional 
reactions, thoughts, how it felt in the body, ease/difficulty of the exercise)  
V. Closing the Session 
Did the therapist do the following (indicate only presence or absence):  
Yes      No  (7) Assign daily LKM exercise (toward benefactor, beloved one, self, plus 
neutral person) to be tracked with Meditation Practice Form  
Yes      No  (8) Assign daily Reflection practice: Participant will notice acts of loving-
kindness that they receive from neutral people in daily life and reflect on 
how the thoughts, emotions, and sensations they experience. 
Yes      No  (9) Complete at least 5 minutes of mindfulness of breath meditation to end 
session 
Session Duration:  
Yes      No  (10) Session duration is between 60-90 minutes?  
Disallowed interventions:  
Yes     No  (11) Therapist did NOT implement interventions that are not included in 
this manual or model of treatment (e.g., formal cognitive restructuring, 
behavioral activation)? 
If “No,” describe:  
________________________________________________________________ 
Adherence Summary Score:  
Total “Yes” _____ / (Total “Yes” _____ + Total “No” _____) = Total Adherence Score 
_____ 
Overall Therapist Rating:  
(8) Please provide an overall rating for therapist during this treatment session, taking into 
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consideration how effectively the therapist presented key treatment elements and met the 
primary goals of the session.  
0 1 2 3 4 5 
Poor Marginal Fair Adequate Good Excellent 
 
Overall Session Rating:  
(8) Please provide an overall rating for this treatment session, taking into consideration 
the therapist’s ability to maintain rapport, engage in collaborative treatment dialogue, 
manage the session, and effectively deliver treatment concepts.  
0 1 2 3 4 5 
Poor Marginal Fair Adequate Good Excellent 
 
(9) Pass/Fail: 
___Pass  ___ Fail  
Note: “Pass” = (1) The session duration is between 60-90 minutes in length AND (2) No 
significant disallowed interventions were administered AND (3a) total adherence score is 
80% or greater OR (3b) the overall session was rated as being at least “Adequate.”  
 
 
Loving-kindness Meditation for Mood and Anxiety Disorders 
Therapist Adherence Rating Scale 
Session 6 (75 minutes) 
Subject ID: _________    Rater Initials: _________  
Session Date: _________    Date Rated: _________  
I. Opening the Session 
Did the therapist do the following (circle yes or no to indicate presence / absence):  
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Yes      No  (1) Complete at least 5 minutes of breathing meditation in the first half of 
session 
Yes      No  (2) Review homework assigned and assess for any difficulty with 
completing the homework forms 
II. LKM to Difficult Person Practice 
Did the therapist do the following (indicate only presence or absence):  
Yes      No  (3) Discuss reactions to topic of directing kindness towards difficult 
person 
Yes      No  (4) Help participant choose / visualize an appropriate difficult person for 
LKM practice 
Yes      No  (5) Psychoeducation on (1) the difference between loving-kindness and 
accepting hurtful behavior and (2) the difference between loving-kindness 
and sentimental love 
Yes      No  (6) Complete LKM towards: the benefactor, a beloved one, the self, a 
neutral person, then a difficult person (order of meditation targets is 
flexible, but with the goal of extended meditation on a difficult person) 
Yes      No  (7) Discuss participant’s reaction to this exercise (e.g., emotional 
reactions, thoughts, how it felt in the body, ease/difficulty of the exercise)  
V. Closing the Session 
Did the therapist do the following (indicate only presence or absence):  
Yes      No  (8) Assign formal daily LKM exercise (toward benefactor, beloved one, 
self, plus neutral person) to be tracked with Meditation Practice Form  
Yes      No  (9) Assign daily Reflection practice: Participant will observe the actions of 
difficult people encountered in everyday life and reflect on how difficult, 
annoying, or irritating actions may be a misguided attempt to find 
happiness. 
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Yes      No  (10) Assign daily informal LKM practice of Sending Kindness to difficult 
people 
Yes      No  (11) Complete at least 5 minutes of mindfulness of breath meditation to 
end session 
Session Duration:  
Yes      No  (12) Session duration is between 60-90 minutes?  
Disallowed interventions:  
Yes     No  (13) Therapist did NOT implement interventions that are not included in 
this manual or model of treatment (e.g., formal cognitive restructuring, 
behavioral activation)? 
If “No,” describe:  
________________________________________________________________ 
Adherence Summary Score:  
Total “Yes” _____ / (Total “Yes” _____ + Total “No” _____) = Total Adherence Score 
_____ 
Overall Therapist Rating:  
(8) Please provide an overall rating for therapist during this treatment session, taking into 
consideration how effectively the therapist presented key treatment elements and met the 
primary goals of the session.  
0 1 2 3 4 5 
Poor Marginal Fair Adequate Good Excellent 
 
Overall Session Rating:  
(8) Please provide an overall rating for this treatment session, taking into consideration 
the therapist’s ability to maintain rapport, engage in collaborative treatment dialogue, 
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manage the session, and effectively deliver treatment concepts.  
0 1 2 3 4 5 
Poor Marginal Fair Adequate Good Excellent 
 
(9) Pass/Fail: 
___Pass  ___ Fail  
Note: “Pass” = (1) The session duration is between 60-90 minutes in length AND (2) No 
significant disallowed interventions were administered AND (3a) total adherence score is 
80% or greater OR (3b) the overall session was rated as being at least “Adequate.”  
 
Loving-kindness Meditation for Mood and Anxiety Disorders 
Therapist Adherence Rating Scale 
Session 7 (75 minutes) 
Subject ID: _________    Rater Initials: _________  
Session Date: _________    Date Rated: _________  
I. Opening the Session 
Did the therapist do the following (circle yes or no to indicate presence / absence):  
Yes      No  (1) Complete at least 5 minutes of breathing meditation in the first half of 
session 
Yes      No  (2) Review homework assigned and assess for any difficulty with 
completing the homework forms 
II. LKM to Groups & All Living Beings Practice 
Did the therapist do the following (indicate only presence or absence):  
Yes      No  (3) Discuss rational for practicing LKM towards groups, to increase 
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awareness of barriers, resistances, and ideas of division and meet these 
emotions and ideas with open-heartedness 
Yes      No  (4) Help participant choose / visualize groups to target in LKM practice 
Yes      No  (5) Introduce concept of expanding LKM to all living beings  
Yes      No  (6) Complete LKM towards: the benefactor or a beloved one, then groups, 
then all living people, creatures, and beings. 
Yes      No  (7) Discuss participant’s reaction to this exercise (e.g., emotional 
reactions, thoughts, how it felt in the body, ease/difficulty of the exercise)  
III. Discuss of Progress, Goals, and Termination 
Did the therapist do the following (indicate only presence or absence):  
Yes      No  (8) Review patient’s experience in treatment (e.g., progress, overcoming 
obstacles to practicing, impact of meditation on daily experiences) 
Yes      No  (9) Find out what patient found most/least helpful 
Yes      No  (10) Discuss patient’s plan to continue LKM practice 
V. Final Closing Meditation 
Did the therapist do the following (indicate only presence or absence):  
Yes      No  (11) Complete at least 5 minutes of final breathing meditation  
Session Duration:  
Yes      No  (12) Session duration is between 60-90 minutes?  
Disallowed interventions:  
Yes     No  (13) Therapist did NOT implement interventions that are not included in 
this manual or model of treatment (e.g., formal cognitive restructuring, 
behavioral activation)? 
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If “No,” describe:  
________________________________________________________________ 
Adherence Summary Score:  
Total “Yes” _____ / (Total “Yes” _____ + Total “No” _____) = Total Adherence Score 
_____ 
Overall Therapist Rating:  
(8) Please provide an overall rating for therapist during this treatment session, taking into 
consideration how effectively the therapist presented key treatment elements and met the 
primary goals of the session.  
0 1 2 3 4 5 
Poor Marginal Fair Adequate Good Excellent 
 
Overall Session Rating:  
(8) Please provide an overall rating for this treatment session, taking into consideration 
the therapist’s ability to maintain rapport, engage in collaborative treatment dialogue, 
manage the session, and effectively deliver treatment concepts.  
 
0 1 2 3 4 5 
Poor Marginal Fair Adequate Good Excellent 
 
(9) Pass/Fail: 
___Pass  ___ Fail  
Note: “Pass” = (1) The session duration is between 60-90 minutes in length AND (2) No 
significant disallowed interventions were administered AND (3a) total adherence score is 
80% or greater OR (3b) the overall session was rated as being at least “Adequate.”  
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